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Abstract
1Information relating to attention-deﬁcit/hyperactivity disorder (AD/HD) has ﬂooded the
consumer and medical markets in recent years. Information “overload” is often problematic,
but it is especially the case with AD/HD. Those aﬄicted with the disorder are uniquely
unsuited to make sense of the mass of information that is presented to them. The purpose
of this article, therefore, is to examine whether any legal controls exist to regulate the
ﬂow of information on AD/HD. The author looks at three of the most important sources
of information on the disorder—the schools, the media, and doctors—and discusses the
possibility of regulation in each area. With regard to the AD/HD information emanating
from the schools, he notes that Congress has already attempted regulation with the proposed
Child Medication Safety Act of 2003. Although the bill did not ultimately become law,
its mere existence shows the understanding of many legislators that regulatory control of
AD/HD information is important. As to the media, the author writes that regulation in
this area is desperately needed. However, as a result of certain constitutional and statutory
limitations, he believes that such regulation is not likely to be forthcoming anytime soon.
Finally, the author describes several attempts that have been made to regulate doctors and
the way in which they receive and dispense information about AD/HD. After noting how
these attempts have generally failed to produce results, he goes on to state his belief that
substantive and eﬀective regulation in this area is a task that is easily achievable.
I.
Introduction
Meet Frank Alexander. Frank is a ﬁrst-year student at Harvard Law School, and at the moment, he is sitting
in one of his required courses, Civil Procedure. The professor, wearing a three-piece suit and large spectacles,
is walking up and down the aisles of the lecture hall, reciting the facts of the landmark case, Pennoyer v.
Neﬀ.1 Frank, however, is not listening. He is looking out the window, where he sees a groundskeeper mowing
the lawn. He watches the man and follows him as he pushes the mower. The groundskeeper, however, soon
moves out of sight, and Frank begins to ﬁdget in his seat—that is, until he looks out the window again
and catches sight of an attractive young lady walking by. He follows her gait along the nearby path until,
suddenly, he notices the professor standing ominously over him, asking, “Mr. Alexander? Are you with us?
1Pennoyer v. Neﬀ, 95 U.S. 714 (1877).
2Will you please answer my question?” Frank, having been distracted by the people outside, does not know
what the professor is talking about and stares back blankly. Frustrated by his student’s inattentiveness, the
professor glares at Frank for a moment and then turns to Frank’s neighbor, Sylvia Davis. “Ms. Davis,” he
says, “Perhaps you can help out Mr. Alexander and answer my question. Mr. Alexander does not seem
to care about his legal education.” Sylvia, who has already made it clear to everyone in the class that she
intends to make law review, answers the question with alacrity, and as she does so, Frank slides down in his
chair, embarrassed about being the center of this kind of attention. These sorts of things seem to happen
all the time to him, and he has developed quite a reputation among his fellow students. What Frank does
not realize, though, is that he may be suﬀering from attention-deﬁcit/ hyperactivity disorder, or AD/HD.2
AD/HD is a condition characterized by one or more of the following symptoms: inattention, hyperactivity,
and impulsivity. The most common attribute of people with the disorder is the inability to focus. Like Frank,
AD/HD suﬀerers ﬁnd that their minds wander, and they are typically disorganized and forgetful. They do
not ﬁnish assignments, whether at school or at work. In those rare instances when they do manage to ﬁnish,
the work is usually ﬁlled with mistakes. Also, many of those with AD/HD are isolated in their daily lives
and have problems in social settings because of a failure to understand the rules that govern interpersonal
relationships.3 Although the common nature of these symptoms makes diﬃcult any estimation of the actual
number of people suﬀering from the disorder, most well-informed observers agree that approximately one to
two percent of the child population, as well as two to four percent of adults, suﬀer from AD/HD.4
2This introduction is modeled on excerpts from two diﬀerent sources: Kristin E. Behrendt, “The Hatch-Waxman
Act: Balancing Competing Interests or Survival of the Fittest?” 57 Food Drug L.J. 247 (2002); Ken Liv-
ingston, “Ritalin: Miracle Drug or Cop-Out?” The Public Interest, No. 127 (Spring 1997), pp. 3-18, online at
http://www.pbs.org/wgbh/pages/frontline/shows/medicating/readings/publicinterest.html. Frank Alexander is a ﬁctional
character, as is Sylvia Davis.
3Livingston, supra note 2.
4Although the disorder was long thought to aﬀect only children, doctors now know that it can aﬀect adults as well. Ilina
3In recent years, AD/HD has become extremely controversial. Some researchers believe that the disorder
is biologically-based and that the inattention, hyperactivity, and impulsivity characteristic of the condition
are attributable to problems with a person’s brain chemistry. As such, those adhering to this view argue
that medication with psychostimulant drugs is the best, and sometimes only, treatment for the disorder.
Others, however, believe that AD/HD is a man-made construct and that prescription of psychostimulant
medication is a reprehensible practice, especially when children are involved. Advocates of this position
claim that psychostimulants are dangerous and addicting substances that serve only to enrich psychiatrists
and pharmaceutical companies and argue that there is nothing physically wrong with people who think they
have AD/HD.5 Improvements in parenting, teaching, and the environment are all that are needed to solve
the problems of these individuals.6
Each side in this debate has put forth an overwhelming amount of information to support its position.
Articles supporting these diﬀerent views of AD/HD appear constantly in books, newspapers, and magazines,
as well as on the Internet. Physicians, school teachers, psychologists, and a variety of self-help groups also
contribute to the body of material about the disorder. Academic research on AD/HD continues at a frenzied
pace, and new studies relating to the condition are released almost every week.7
Singh, A Crutch, A Tool: How Mothers and Fathers of Boys with AD/HD Experience and Understand the Work of Ritalin.
Harvard University Graduate School of Education Ed.D. Dissertation (2000), p. 8. The oﬃcial psychiatric view is that three
to ﬁve percent of children suﬀer from AD/HD, but this ﬁgure is considered by many experts to be inﬂated. Statement of
William Carey, M.D., Director of Behavioral Pediatrics, Children’s Hospital of Philadelphia, in Protecting Children: The Use
of Medication in Our Nation’s Schools and H.R. 1170, Child Medication Safety Act of 2003. Hearing Before the Subcommittee
on Education Reform of the Committee on Education and the Workforce, United States House of Representatives, 108th
Congress, May 6, 2003 (Washington, D.C.: U.S. Government Printing Oﬃce, 2003), online at http://wwws.house.gov; Lisa
Belkin, “Oﬃce Messes,” The New York Times Magazine, July 18, 2004, p. 26.
5Singh 18.
6As Lawrence Diller explains, these two positions represent the familiar “nature versus nurture” argument. Lawrence Diller,
Running on Ritalin (New York: Bantam Books, 1998), p. 10.
7Statement of Lance Clawson, in Protecting Children, supra note 4.
4More often than not, those who produce all this information believe that they are serving an important
public purpose—to educate others about AD/HD. What they fail to understand, however, is that too much
information in the public arena can undermine their eﬀorts. These days, anyone who engages all the diﬀerent
authorities on AD/HD in an attempt to learn about the disorder is confronted with so many diﬀerent facts—
many of which directly contradict one another—that he or she is likely to walk away confused, rather than
well informed. There is no clarity in the debate about AD/HD, and it is never clear what facts are valid
and what facts are not. Evidence can be found to support almost any position.8 Needless to say, this is
extremely frustrating for those who may be aﬄicted with the disorder.9 It also poses problems for doctors,
mental health workers, law enforcement oﬃcials, teachers, school administrators, and policy makers who
seek out information about AD/HD because they have to deal with it on a daily basis.
To be sure, information “overload” is not unique to AD/HD. A number of factors, however, combine to
make the problem particularly acute in the case of the disorder. First, AD/HD, in a variety of forms, has
been around for a long time, so a lot of information about it has been produced over the years. Second, it
is a disorder in which the diagnostic process is particularly elastic. There is no objective, scientiﬁc test for
AD/HD, and doctors disagree about the best methods of evaluation and diagnosis. Each physician seems
to follow a diﬀerent procedure when confronted with AD/HD-type symptoms. With such confusion in the
8Diller 314.
9The drafters of the 1998 National Institutes of Health AD/HD Consensus Conference Statement recognized these problems.
They wrote: “Families of children impaired by the symptoms of AD/HD are in a very diﬃcult position. An already painful
decision-making process is often made substantially worse by the media war between those who overstate the beneﬁts of
treatment and those who overstate the dangers of treatment.” Cited in testimony of Bob Seay before the Arkansas House of
Representatives, House Interim Committee on Public Health, Welfare, and Labor, May 3, 2000, included in Ritalin Use Among
Youth: Examining the Issues and Concerns. Hearing before the Subcommittee on Early Childhood, Youth and Families
of the Committee on Education and the Workforce, United States House of Representatives, 106th Congress, May 16, 2000
(Washington, D.C.: U.S. Government Printing Oﬃce, 2000), p. 143.
5medical community, the ready availability of information on the disorder is dangerous, because it makes the
manipulation of fact a particularly easy task. Third, because psychostimulants—drugs that can aﬀect the
very essence of our humanity—are used for treating the disorder, the controversy over AD/HD has aroused
extreme passions.10 It is a ﬁght that is bitter and contentious, and adherents of the diﬀerent views on
AD/HD release information constantly in an attempt to get the better of their opponents. Fourth, and most
importantly, those with AD/HD—due to the nature of the condition and the way in which it prevents people
from focusing on a task for any extended period of time—are uniquely unsuited to make sense of all the
information that is presented to them.
The purpose of this article is to examine whether there are any legal controls that exist to regulate the ﬂow
of information about AD/HD. As might be imagined, this is a diﬃcult subject. AD/HD is a disorder that
has many interested parties—parents, children, teachers, doctors, employers, pharmaceutical companies, and
federal and state governments, to name just a few. Understanding how information ﬂows among these groups
is an extremely complicated endeavor. It is a web that is not easily untangled. Within the legal realm, the
subject lies at the intersection of First Amendment law and food and drug law. And within food and drug
law, one comes up against many of the most diﬃcult and divisive issues of the day—issues such as oﬀ-label
prescribing, direct-to-consumer marketing, and regulation of the pharmaceutical industry.
Despite these diﬃculties, this is an issue that must be addressed. There are a number of reasons for its
importance. First, there are ethical concerns relating to informed consent. When individuals are seeking
10Singh 205.
6information about AD/HD, they should be made aware of the controversy surrounding the disorder. They
should know about the potential side eﬀects of the medications used to treat the condition. They should
be told of studies showing a correlation between psychostimulant use and later drug use. They should also
know that use of certain AD/HD medications could bar a person from military service.11 When children are
involved, these facts must be communicated all the more clearly to parents, because children do not make
the decision themselves about taking medication. Without a clear and accurate presentation of all these
issues, people cannot make informed and educated decisions about what is best for them and the members
of their family.
Second, despite the massive body of literature that has sprung up around AD/HD, there are still people
who are not receiving any information about the disorder. There are many concerns about those individuals
who suﬀer from AD/HD, but who have not been diagnosed and who are not receiving the help they need.12
Researchers have studied this problem in depth.13 For example, in one notable study, they performed
evaluations of 1285 children in four communities—Atlanta, Georgia; New Haven, Connecticut; Westchester
County, New York; and San Juan, Puerto Rico. It turned out that 5.1% of children and adolescents between
the ages of nine and seventeen had AD/HD, yet only 12.1% of these children were being treated with
medication. Results such as these suggest that a great many people with the disorder are not receiving
11These concerns were articulated by Patricia Weathers, President, Parents for Label and Drug Free Education. See Statement
of Patricia Weathers in Attention-Deﬁcit/Hyperactivity Disorder—Are We Overmedicating Our Children? Hearing before the
Committee on Government Reform, United States House of Representatives, 107th Congress, September 26, 2002 (Washington,
D.C.: U.S. Government Printing Oﬃce, 2003), online at http://frwebgate.access.gpo.gov.
12American Academy of Child and Adolescent Psychiatry (AACAP), Practice Parameters for the Assessment and Treatment
of Children, Adolescents, and Adults With Attention-Deﬁcit/Hyperactivity Disorder, cited in Clawson, supra note 7. According
to the American Medical Association (AMA), many AD/HD children go undiagnosed and untreated as a result of misinformation
about the disorder.
13Dr. Peter Jensen is the Ruane Professor of Child Psychiatry at Columbia University. He was formerly the Associate
Director for Child and Adolescent Research at the National Institute of Mental Health (NIMH).
7appropriate treatment.14 Also, signiﬁcant geographic diﬀerences in the prescription of psychostimulant
medication make one suspect that there are problems with information ﬂow. There are tremendous variations
from community to community. In certain Virginia school districts, one out of every six white males in the
ﬁfth grade uses a psychostimulant drug.15 Yet, in other counties throughout the United States, not a single
person receives psychostimulant medication.16 If these disparities are indeed the result of a system-wide
failure to get people the information they need, steps must be taken to improve this situation.17
Third, and more generally, we aim, as a society, for an economically eﬃcient allocation of resources—in other
words, resources should be put to their most productive uses. Under the practices currently used to diagnose
and treat AD/HD, however, the allocation of resources is extremely unproductive. This is evident when
looking, for example, at the phenomenon of direct-to-consumer advertising. Various advertisements for new
AD/HD drugs and treatment modalities have ﬂooded the media in recent years. One can hardly turn on
the television or read a newspaper and not see an advertisement for an AD/HD medication. Although these
14AACAP Practice Parameters, supra note 12. See Peter Jensen, et al., “Are Stimulants Overprescribed? Treatment of
AD/HD in Four U.S. Communities,” Journal of the American Academy of Child and Adolescent Psychiatry 38:7 (July 1999);
Peter Jensen, “Is AD/HD Overdiagnosed and Overtreated? A Review of the Epidemiological Evidence,” Report on Emotional
and Behavioral Disorders in Youth 2:4 (Fall 2003).
15Statement of Lawrence Diller, in Ritalin Use Among Youth, supra note 9.
16Problems with geographic distribution are evident from a variety of sources. The Drug Enforcement Administration (DEA)
has a system known as ARCOS (Automation of Reports and Consolidated Orders System) that tracks certain controlled
substances from point of manufacture to the location where the drugs are distributed to consumers. ARCOS data shows that
there is wide variability in the use of certain psychostimulants from one state to another and from one community to another
within states. Also, reporters from The Cleveland Plain Dealer studied for one full year the actual prescriptions written in
every county in the nation. Some counties had 20% of school-age boys on psychostimulant medication while other counties had
practically no one receiving stimulant medication. See Sabrina Eaton and Elizabeth Marchak, “Ritalin Prescribed Unevenly
in U.S.,” The Cleveland Plain Dealer, May 6, 2001, p. 1A. Finally, in the February 2003 issue of Pediatrics, the professional
journal of the American Academy of Pediatrics (AAP), researchers documented the signiﬁcant “geographical variation in the
prevalence of stimulant medication use.” Emily R. Cox, et al., “Geographic Variation in the Prevalence of Stimulant Medication
Use Among Children 5 to 14 Years Old: Results from a Commercially Insured U.S. Sample,” Pediatrics 111: 237-243 (February
2003).
17That people are not being treated may not be the result of information failures, but rather of conscious rejection of the
information once it is presented. The condition already has become trivialized by the growing numbers of cases being diagnosed.
As a result, people may simply dismiss the information once they receive it. Also, certain racial and ethnic groups look down
upon the mental health system in general and the AD/HD diagnosis in particular. For example, many African-Americans do
not go to medical specialists for behavior and performance problems because they fear doctors’ use of drugs. Crack cocaine
has been so injurious to the black community that many blacks are apprehensive about using any kind of stimulant. Similarly,
many Asian immigrants living in the United States are not comfortable using the mental health system to solve their problems.
Such cultural diﬀerences are understandable. As Lawrence Diller relates, “Cultures diﬀer in the degree to which their members
accept emotional distress or tolerate underperformance. They also vary in how people feel about seeking professional assistance
for emotional problems and in their acceptance or disapproval of drugs to relieve distress or improve performance.” Diller 316.
8advertisements do serve many valuable purposes, they also make it more likely that scarce medical resources
are devoted to issues that may not actually be urgent. There is abundant evidence that in the few minutes
that a patient usually spends with his doctor, he spends much of the time talking about what he has seen in
these advertisements.18 Similarly, a diagnosis of AD/HD often provides access to certain specialized medical
and educational resources. However, the use of these resources by people who are given an AD/HD diagnosis
when it is not warranted limits the resources available for those who are truly disabled. Information controls
can go a long way toward ensuring that resources are being allocated in ways that provide the maximum
beneﬁt.19
To explore these issues, Part II of this article will take a closer look at AD/HD, its history, and the way
it has been treated over the years. I will then examine in detail three of the most important vehicles for
information about the disorder. Part III will explore the school system in general and the role of teachers
in particular. Part IV will focus on the media, looking at two speciﬁc areas: the Internet and direct-to-
consumer advertising. Part V will examine the role of physicians in the AD/HD diagnostic and treatment
process. Finally, Part VI will provide conclusions and discuss ways to improve the ﬂow of information about
the disorder.
II. AD/HD, its history, and methods of treatment
18Stephen J. Ceccoli, Pill Politics: Drugs and the FDA (Boulder: Lynne Rienner Publishers, 2004), pp. 156-157.
19It should be noted that the presentation of so much information about AD/HD—much of which is devoted to the use
of medication for treatment of the disorder—also has the potential to undermine the nation’s war on drugs. A television
advertisement warning children about the dangers of drugs may very well be followed by one pushing a psychostimulant or
other drug. As Ken Livingston has written, “There is something odd, if not downright ironic, about the picture of millions of
American school children ﬁling out of ‘drug-awareness’ classes to line up in the school nurse’s oﬃce for their midday dose of
amphetamine.” Livingston, supra note 2. Mary Eberstadt has stated the problem diﬀerently: “How has it come to pass that
in ﬁn-de-si` ecle America, where every child from preschool onward can recite the ‘anti-drug’ catechism by heart, millions of
middle- and upper-middle class children are being legally drugged with a substance so similar to cocaine that, as one journalist
accurately summarized the science, ‘it takes a chemist to tell the diﬀerence’?” Mary Eberstadt, “Why Ritalin Rules,” Policy
Review 94 (April & May 1999), online at http://www.policyreview.org/apr99/eberstadt.html.
9There are certain individuals who simply cannot focus on a task for an appropriate period of time.20 This is
more than the typical inattention and restlessness that plagues us all occasionally; the lack of focus in people
with AD/HD is constant and pervasive. Because most people do not understand the debilitating nature
of the disorder, those suﬀering from AD/HD and others familiar with the condition often use a number of
colorful analogies to describe what the AD/HD-aﬄicted experience on a daily basis. “AD/HD is like having
thirty televisions on at one time, and the medicine turns oﬀ twenty-nine so you can concentrate on the
one,” says Kerri Houston, national ﬁeld director for the American Conservative Union and the mother of
two AD/HD children.21 Dr. Andrew P. Levin, clinical director of the outpatient mental health service of
the Westchester division of the St. Vincent’s Catholic Medical Center of New York, uses a diﬀerent analogy.
“Trying to function with untreated [AD/HD] is like driving through the rain without windshield wipers,” he
says.22 And Robert Tudisco, a lawyer with AD/HD who also represents clients with the disorder, opts for
yet another approach: “As I sit here and talk to you in a relatively calm conversation, there’s an amusement
park going on in my head.”23
As suggested above, these problems come with tremendous consequences. AD/HD can lead to disorgani-
zation, forgetfulness, school failure, poor social relationships, underperformance at work, chronic drug use,
and brushes with the law. A never-ending cycle of employment and unemployment is also common.24 Some
AD/HD suﬀerers, however, are more likely than others to experience these problems. This is because there
are three distinct subtypes of the disorder—an inattentive subtype, a hyperactive-impulsive subtype, and
20Statement of Richard K. Nakamura, Acting Director, NIMH, in Attention-Deﬁcit/Hyperactivity Disorder, supra note 11.
21Michael Fumento, “Trick Question,” The New Republic, February 3, 2003, p. 18.
22“Attention Deﬁcit: Not Kids Only!” The New York Times Magazine, October 29, 2000, p. 46.
23Belkin 27.
24“International Consensus Statement on AD/HD,” in Clinical Child and Family Psychology Review 5:2 (June 2002), p. 92.
10a combined subtype. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM), the
oﬃcial handbook of psychiatric illness, the inattentive subtype exists when people exhibit at least six of
nine inattention symptoms listed in the DSM and no more than ﬁve hyperactive-impulsive behaviors. The
hyperactive-impulsive subtype is seen in those people who display at least six of nine hyperactive-impulsive
symptoms but less than six inattention symptoms. And the combined subtype is found in people who ex-
hibit at least six inattention and at least six hyperactive-impulsive symptoms.25 Whether a person with the
disorder experiences social isolation or problems at work depends in large part on what kind of AD/HD he
has.
In an attempt to explain such phenomena, researchers have looked into the biological causes of AD/HD. The
disorder has been linked to several speciﬁc brain regions, especially the frontal lobe, the basal ganglia, and
the cerebellum. Those with AD/HD usually have less electrical activity and less reactivity to stimulation
in these areas of the brain.26 There are also volumetric diﬀerences and diﬀerences in metabolic activity
in the brains of those with AD/HD.27 Relying heavily on such research, the U.S. Surgeon General, the
American Medical Association, the American Psychiatric Association, the American Academy of Child and
Adolescent Psychiatry, the American Psychological Association, and the American Academy of Pediatrics
25George J. DuPaul and Gary Stoner, AD/HD in the Schools (New York: The Guilford Press, 2003), p. 26. Whatever
subtype is at issue, doctors require that other criteria be met as well. For example, symptoms of the disorder must have begun
prior to age seven; the child or adult must demonstrate the problem behaviors in at least two situations (school, home, or work);
the behaviors must cause signiﬁcant distress or impairment in functioning; and the behaviors cannot be better explained by
other diagnostic conditions. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV-TR) (Washington, D.C.: American Psychiatric Association, 2000), pp. 83-85; Diller 56.
26“International Consensus Statement on AD/HD,” supra note 24. See, e.g., R.A. Barkley, et al., “Frontal lobe functions in
attention deﬁcit disorder with and without hyperactivity: A review and research report,” Journal of Abnormal Child Psychology
20 (1992), pp. 163-188; M. Teicher, et al., “Functional deﬁcits in basal ganglia of children with attention-deﬁcit/hyperactivity
disorder shown with functional magnetic resonance imaging relaxometry,” Nature Medicine 6 (2000), pp. 470-473.
27AD/HD brains are generally smaller. Research using magnetic resonance imaging (MRI) and positron emission tomography
(PET) found that total brain size in subjects with AD/HD is approximately three to ﬁve percent smaller than in age- and
gender-matched control subjects. Belkin 27.
11have all recognized AD/HD as a legitimate disorder.28 Also, in 2002, an international group of scientists
released a statement supporting the AD/HD diagnosis.29
If an individual suspects that he has AD/HD, a comprehensive evaluation by a specially trained professional is
essential.30 This is easier said than done, however. For a number of reasons, AD/HD is not an easy diagnosis
for doctors to make.31 First, as was mentioned above, there is no conﬁrmatory test for the disorder. Second,
with AD/HD, there is a high degree of co-morbidity, which means that many people with the disorder also
experience other psychiatric problems.32 It is often diﬃcult for doctors to distinguish these problems from
AD/HD. Third, the diagnostic criteria for AD/HD are in many ways a collection of common behaviors.
Many people ﬁdget with their hands, are inattentive, and avoid boring tasks. Therefore, it is up to the
doctor to evaluate the frequency, intensity, and degree of impairment in a patient.33 But this, in turn, is an
impressionistic and subjective process. Results are very much open to interpretation.34
Should a doctor actually diagnose an individual with AD/HD, the National Institute of Mental Health
(NIMH) gives doctors advice on how to treat the disorder. NIMH guidelines prescribe what has come to be
known as “multimodal” treatment. This includes behavioral therapy, counseling, special education interven-
tions, and potential medication use. Multimodal treatment, however, is labor-intensive and expensive.35 As
a result, although such eﬀorts may be recommended as part of a treatment plan and although many doctors
28“International Consensus Statement on AD/HD,” supra note 24.
29Id.; Statement of Richard K. Nakamura, supra note 20.
30Statement of Richard K. Nakamura, supra note 20.
31AACAP Practice Parameters, supra note 12.
32A study conducted by the NIMH showed that 69% of children with AD/HD have co-occurring disorders. In other words,
only 31 percent of children with AD/HD have AD/HD alone with no other disorder. The study found that 40 percent of
children with AD/HD had oppositional deﬁant disorder, 34 percent had anxiety disorder, 14 percent had conduct disorder, and
four percent had a mood disorder. Children with auditory or visual problems can also exhibit AD/HD symptoms.
33Diller 58.
34Statement of William Carey, supra note 4; Diller 61-62. As the author Lisa Belkin relates, to many, the disorder is “little
more than spaciness redeﬁned as a disease.” This is because the symptoms look suspiciously like bad habits. Belkin 26-27.
35Diller 45.
12ascribe to multimodal treatment in theory, in practice the NIMH guidelines are rarely followed.36
Psychostimulant therapy is usually the only treatment provided.37 Psychostimulant medication increases
the availability of neurotransmitters such as dopamine and norepinepherine in certain parts of the brain.
This speeds up the activity of neurons and results in a greater arousal of the central nervous system.
This, in turn, provides better executive function and increased attention and behavior control.38 The most
commonly employed psychostimulants are methylphenidate hydrochloride (hereinafter, methylphenidate),
dextroamphetamine, and mixed amphetamine.39 Methylphenidate, however, is used most widely. Over 80%
of children treated with psychostimulants use some form of the drug on a daily basis.40
Side eﬀects of the psychostimulants can include sleeplessness, weight loss, growth retardation, heart damage,
and psychosis. There has also been concern that these drugs impact cognitive processes. AD/HD expert
Lawrence Diller writes, “Both parents and researchers have at times noticed that children taking psychostim-
ulants sometimes answer questions in ways that seem overly compliant or narrow, suggesting that the drug
36Id.
37Approximately 1.5 million children in the United States are treated with psychostimulant medications. Daniel Safer
and Julie Magno Zito, “Pharmacoepidemiology of methylphenidate and other stimulants for the treatment of AD/HD,” in
Laurence L. Greenhill and Betty B. Osman, eds. Ritalin: Theory and Practice (Larchmont: Liebert, 2000), pp. 7-26.
Data on physician prescribing practices suggest that few general practitioners or pediatricians provide treatment other than
pharmacotherapy with psychostimulants. Drug and Chemical Evaluation Section, Oﬃce of Diversion Control, Drug Enforcement
Administration (DEA), United States Department of Justice, “Methylphenidate: A Background Paper,” October 1995, online
at http://ablechild.org/dea%20report %2010-1-95.htm.
38Executive function includes short-term memory, as well as the ability to plan and stay focused on a task without being
distracted by emotional impulses. See Dr. Thomas E. Brown, ed., Attention-Deﬁcit Disorders and Comorbidities in Children,
Adolescents, and Adults (Washington, D.C.: American Psychiatric Press, 2000).
39Other examples of psychostimulants include caﬀeine and cocaine.
40DuPaul and Stoner 191; Safer and Zito, supra note 37. Methylphenidate is sold as the brand-name medications “Concerta”
and “Ritalin.” Dextroamphetamine goes by the trade name “Dexedrine,” and mixed amphetamine is sold most commonly as
“Adderall.”
13might restrict creative thinking.”41 Partly as a response to these side eﬀects, pharmaceutical companies have
worked in recent years to develop nonstimulant medications to treat AD/HD. At the end of 2002, the U.S.
Food and Drug Administration (FDA) approved atomoxetine, better known by its trade name “Strattera,” a
nonstimulant sold by Eli Lilly and Company.42 Strattera allows people to take on certain jobs—for example,
machine operation or airline piloting—that would be dangerous under the inﬂuence of psychostimulants.43
It is also the ﬁrst medication speciﬁcally designed for AD/HD in adults.44 The drug, however, has not been
extensively studied, and debate continues about its eﬀectiveness.
The earliest report we have of individuals who would ﬁt the modern AD/HD diagnosis dates back to 1902.
Lecturing before the Royal Academy of Physicians in London, doctor George Still described a certain group
of children as “aggressive,” “deﬁant,” “resistant to discipline,” “excessively emotional,” and “passionate.”
He also noted how these children manifested little “inhibitory volition.”45 We do not hear much more about
this collection of symptoms until 1917-1918, when an outbreak of encephalitis, a viral infection of the brain,
piqued the interest of researchers. Doctors examined children who experienced behavioral and cognitive
problems after their illness, and they found pervasive evidence of inattention, hyperactivity, and impulsivity.
Over the course of the next decade, researchers studied these symptoms sporadically, and by the 1930s, they
had come up with names such as “organic drivenness” and “restlessness syndrome” for this set of problems.46
41Diller 26.
42Strattera prevents the reuptake of norepinephrine, a neurotransmitter believed to be important in regulating attention,
impulsivity, and activity levels. The reuptake inhibition mechanism keeps more norepinephrine at work in the synapses. Demian
Faunt, “Attention to details: intensiﬁed promotion of Strattera to physicians emphasizes nonstimulant and noncontrolled status,
which translates into a strong sales start,” Med Ad News, October 1, 2003, p. 38.
43Belkin 29.
44DuPaul and Stoner 194.
45G.F. Still, “Some abnormal psychical conditions in children.” Lancet 1: 1008-12, 1077-82, 1163-68 (1902); Diller 51.
46Diller 51-52.
14It was, however, only in the early 1940s that the condition began to be studied in depth. Doctors focused
in on a speciﬁc group—children who, because of a presumed problem with their nervous systems, had learn-
ing disabilities. Although no evidence of damage to the brain could be found in most of these children,
it was believed that they did have brain damage because they experienced the same learning problems as
individuals who were known to have suﬀered brain injury (e.g., after trauma). In these subjects, however,
doctors believed that the brain injury was so small that it was undetectable. Therefore, they introduced
the term “minimal brain damage” (MBD) to describe the cause of these children’s deﬁcits.47 Over the
years, MBD came to be a broad diagnosis and included a number of behaviors that resemble the symp-
toms of modern AD/HD, including hyperactivity, distractibility, and impulsivity.48 However, some medical
providers—particularly those who remained faithful to the art of psychoanalysis—did not use the MBD
terminology and instead opted for the more ambiguous diagnosis of “emotional disturbance” to describe the
AD/HD-like symptoms they came across.
Throughout the 1950s, psychoanalysts and psychiatrists cooperated in what was seen as a common eﬀort
to help those suﬀering from behavioral and emotional problems. By the end of the decade, however, this
cooperation had largely come to an end. Many psychiatrists were frustrated with psychoanalysis and its
lack of tangible results in treating MBD/emotional disturbance, and they decided to emphasize the organic
nature of the disorder. They were aided by two developments. First, in 1957, Maurice Laufer coined a
new name—“hyperkinetic disorder of childhood”—to describe the constellation of symptoms that character-
ized MBD/emotional disturbance. Laufer, writing in the Journal of Pediatrics, discussed MBD’s “organic
components,” narrowed its symptoms to one in particular (hyperactivity), and recommended amphetamine
47Statement of David Fassler, in Attention-Deﬁcit/Hyperactivity Disorder, supra note 11.
48Other behaviors included “excessive restlessness, poor ability to sustain interest in activities, aimless wandering, and
excessive appetite.” Diller 52. By the 1950s, MBD was changed to “minimal brain dysfunction.”
15for treatment.49 After publication of this article, doctors began to urge their colleagues to compensate for
their prior neglect of biology.50 In journals and other trade publications, they encouraged “the considera-
tion of organic factors when diagnosing children’s behavior because the psychogenic factors have so often
been exclusively emphasized.”51 They also told their colleagues to look “as carefully among the myriad of
possibilities of organic causation as [they did] in the past among the interpersonal, deprivation and stress
factors.”52
The second important development during this period was the appearance of Ritalin, a new psychostimulant
marketed by Ciba Pharmaceuticals.53 Ritalin was not initially intended as a treatment for hyperkinetic
disorder of childhood. Rather, it was designed for mild depression and narcolepsy. The appearance of
Ritalin, however, was important because by this time, there were many studies that established that psy-
chostimulants lessened hyperactivity, and doctors understood how these medications worked (see below).54
Furthermore, with Laufer’s new biological paradigm, there was a clear role for the psychostimulants. Doctors
therefore prescribed Ritalin “oﬀ-label.”55 As use of the drug became more popular, researchers began to
change how they studied hyperkinetic disorder. Lawrence Diller writes, “This was the start of a trend away
from attempts to identify the source of the problems—which was proving so diﬃcult—and toward a more
pragmatic approach: simply sorting out and describing symptoms in detail, and learning what did or did
not lead to improvement.”56
49Maurice Laufer and Eric Denhoﬀ, “Hyperkinetic behavior syndrome in children,” Journal of Pediatrics 50: 463-474 (1957).
50Singh 93-94.
51Id.; M. Knobel, et al., “Hyperkinesis and organicity in children,” Archives of General Psychiatry 1: 310-321 (1959), p. 319.
52Singh 93-94; Sam D. Clements and John E. Peters, “Minimal brain dysfunction in the school-aged child: diagnosis and
treatment,” Archives of General Psychiatry 6: 185-97 (1962), p. 197.
53Ritalin is a brand-name version of methylphenidate.
54Diller 52.
55“Oﬀ-label” prescribing is discussed below in Part V.
56Diller 52.
16It should be noted, however, that the new emphasis on biology, hyperactivity, and medication was not
all-consuming during this period. Despite many doctors advocating a wholesale change in approach, psy-
choanalytic methods were still used by medical providers in treating the symptoms of hyperkinetic disorder.
In the early 1960s, for example, it was still commonly believed that the most eﬀective treatment for the
disorder combined psychotherapy, parental counseling, and psychostimulant medication.
The year 1972, however, marked a key moment in the history of the disorder. In that year, Virginia
Douglas, head of a research team at McGill University in Montreal, delivered a paper to the Canadian
Psychological Association about a group of children that she had been studying. These were children who
had been diagnosed with hyperkinetic disorder, but their problems centered less on hyperactivity and more
on inattention and impulsivity. In fact, many of the kids showed no sign of hyperactivity at all. Douglas
therefore believed that the emphasis on hyperactivity in the diagnosis and treatment of hyperkinetic disorder
was incorrect.57 Instead, she favored an approach whereby hyperactivity was placed on an equal footing with
inattentiveness and impulsivity. In other words, she sought to reverse the earlier emphasis on hyperactivity
initiated by Laufer.
This new approach was supported by other research, and there was soon born a new name for the condition—
attention-deﬁcit disorder, or ADD. This new terminology reﬂected the belief among diagnosticians that
57Id. at 53.
17attention, and not hyperactivity, was the key problem.58 Oﬃcial acceptance of this view came in 1980 with
the introduction of ADD in the DSM-III (the third edition of the DSM). The DSM-III deﬁnition of ADD,
however, was written in such a way that it encompassed millions of people—namely those individuals with
problems of inattention and/or impulsivity without any hyperactivity.59 The text made a clear distinction
between ADD with hyperactivity (ADD/H) and without (ADD/WO).60
After the DSM revisions in 1980, debate continued to rage among mental health professionals about the
importance of hyperactivity in the ADD diagnosis. As the decade progressed, there were increasing concerns
that it had been deemphasized too much. The 1987 revision of the DSM, the DSM-III-R, therefore replaced
“attention-deﬁcit disorder” (ADD) with “attention-deﬁcit/hyperactivity disorder” (AD/HD).61 This change,
however, was made somewhat prematurely. By the time of the 1994 publication of the DSM-IV, diagnosti-
cians believed that the earlier DSM-III distinctions had been more accurate, and they changed the criteria
once again, implementing the current classiﬁcation system with its three subtypes (with inattention only,
with hyperactivity-impulsivity only, and the combined form).62
Throughout much of the history of AD/HD, psychostimulant medications have provided the main form of
treatment for the disorder, and these drugs have a long and complex history of their own. Their power was
discovered accidentally in the mid-1930s by Charles Bradley, a pediatrician who served as the director of
58Singh 11.
59Diller 32, 53.
60Livingston, supra note 2; American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Third
Edition (DSM-III) (Washington, D.C.: American Psychiatric Association, 1980).
61Diller 54. The term “ADD” no longer exists oﬃcially. Most people, however, continue to use the acronym. Lawrence Diller
says the reason for this is not clear: “[P]erhaps [it] is because it is simply easier to say, or perhaps because it more accurately
reﬂects the growing number of children and adults who demonstrate problems only with attention.” Id.
62Livingston, supra note 2.
18the Emma Pendleton Bradley Home in East Providence, Rhode Island, the nation’s ﬁrst psychiatric hospital
devoted to children.63 Bradley worked with kids under fourteen who were of normal intelligence but who
demonstrated a variety of neurological and behavioral disorders.64 Bradley’s discovery was made when he
gave benzedrine, a mixture of two types of amphetamine, to children who had undergone a spinal tap in an
attempt to cure the headaches common after such a procedure. Although the headaches did not disappear,
this experimental treatment regimen decreased the activity level of many of the children and also increased
their compliance and academic performance.65
Bradley ﬁrst published his ﬁndings in 1937 in The American Journal of Psychiatry.66 He noted the children’s
newfound motivation and their enhanced ability to read, comprehend, and do arithmetic. He also stated that
half of the children became “more placid and easy-going.”67 He wrote, “It appears paradoxical that a drug
known to be a stimulant should produce subdued behavior.” Bradley’s observation of “subdued behavior,”
however, was in actuality the children’s intensiﬁed focus.68 Over the years, he and his colleagues continued
their experiments with psychostimulants and published their results in the leading professional journals of
the day.
63The Emma Pendleton Bradley Home opened its doors in 1931 and was equipped mainly for the care of children with
neurologic and behavior disorders. In using benzedrine to cure headaches, Bradley was likely experimenting with diﬀerent
methods of treatment. Ilina Singh writes, “The 1930s was an era of radical experimentation with drug therapies, often based
on a hit or miss premise rather than on theoretical foundations. The drug companies were glad to support such research. In
Bradley’s pioneering article, he thanks Smith, Kline, and French Laboratories for supplying the benzedrine.” Singh 90.
64Id. at 88.
65Diller 24-25. Bradley performed his experiment on twenty-one boys and nine girls, ages ﬁve to fourteen. Singh 88.
66Charles Bradley, “The Behavior of Children Receiving Benzedrine,” 94 Am. J. Psychiatry 577 (1937).
67Id.; Singh 88.
68Bradley, supra note 66; Diller 24-25. In other words, the drug’s eﬀect was not at all paradoxical—the stimulant “stimulated”
the children’s ability to focus.
19The psychostimulant most widely used for the treatment of AD/HD has always been methylphenidate. First
synthesized in Europe in 1944, it was the brainchild of doctors who wanted to prescribe a stimulant that
would not cause addiction.69 It was not until 1955, however, that the drug was approved for use in the
United States by the FDA to treat mild depression and narcolepsy. Its use was limited at this point because
relatively few clinical trials had been conducted on its safety and eﬃcacy. In the late 1950s and early
1960s, however, additional trials were conducted that showed both the power of the drug and its potential
uses, and in 1961, the FDA amended methylphenidate’s oﬃcial list of indications to include treatment for
certain behavior problems.70 By the mid-1960s, Ritalin, the brand-name version of the drug, had become
the primary substance used for the treatment of behavior. An estimated 150,000 children were taking the
medication in 1970.71
In 1971, however, the Drug Enforcement Administration (DEA) imposed restrictions on the psychostimulants
and designated both methylphenidate and amphetamine to be Schedule II drugs under the Controlled Sub-
stances Act (CSA).72 Schedule II is a category that includes drugs with a signiﬁcant risk of abuse.73 These
restrictions by the DEA had several consequences. First, they required quotas to be set on the amount of
psychostimulant medication produced in a given year. The avowed aim of these quotas was two-fold: 1) to
ensure that legitimate medical need was satisﬁed; and 2) to limit the diversion of drugs for illegal purposes.74
69Diller 21.
70Id. at 24-25. According to Lawrence Diller, Ritalin research fueled many grants and academic careers in the 1960s. Id.
71Id. at 27.
7221 U.S.C. § 801. Statement of Terrance Woodworth, Deputy Director, Oﬃce of Diversion Control, DEA, United States
Department of Justice, in Ritalin Use Among Youth, supra note 9.
73Id. For a drug to be classiﬁed as Schedule II, it must meet three criteria: 1) It has to have a high potential for abuse; 2) it
has to have a currently accepted medical use in treatment in the United States; and 3) it has to show that abuse may lead to
severe psychological or physical dependence. Statement of Chairman Dan Burton, in Attention-Deﬁcit/Hyperactivity Disorder,
supra note 11. Schedule I, the most dangerous category, is reserved for heroin, LSD, and other drugs that can be used only
experimentally.
74Section 306(a) of the Controlled Substances Act. Each year, an aggregate production quota (APQ) for each Schedule II
drug is set based on sales and inventory data supplied by the manufacturers, as well as on information supplied by the FDA
20Second, the DEA restrictions required doctors to use special forms whenever they dispensed psychostimulant
drugs.75
Despite this new regulation, psychostimulant use was on the rise by the start of the 1980s. In 1980, it was
estimated that between 270,000 and 541,000 elementary school children in the United States were receiving
psychostimulants on a daily basis. By 1987, this number grew to 750,000.76 These numbers, however, were
relatively low. Records kept by the DEA on the annual production quotas of methylphenidate reveal that
psychostimulant usage simply exploded in the 1990s. In 1990, the methylphenidate quota stood at 1768
kilograms. It rose to 5110 kilograms in 1993, 10,410 kilograms in 1995, and 13,824 kilograms in 1997. By
2000, the quota increased to over 14,000 kilograms.77
III. Schools
In examining the regulation of information relating to AD/HD, we look ﬁrst at the schools. We begin our
inquiry here for a number of reasons. First, a large number of AD/HD suﬀerers are children, and children
spend much of their time in educational settings. Second, the precipitating events leading to the diagnosis
of AD/HD in children almost always occur at school.78 Teachers, who work closely with students and spend
hours each day with them, are usually the ﬁrst to realize that a child might have the disorder. Third,
regarding medical and research needs. The government then gives each company a manufacturing quota (MQ) to provide for
these needs. “Methylphenidate: A Background Paper,” supra note 37.
75This requirement is perceived as burdensome by some doctors and by many patients because prescriptions must be written
in the doctor’s oﬃce rather than phoned in to a pharmacy.
76Diller 33.
77Statement of Terrance Woodworth, supra note 72; Statement of Chairman Michael Castle, in Ritalin Use Among Youth,
supra note 9; “Methylphenidate: A Background Paper,” supra note 37; Diller 33-34.
78Livingston, supra note 2.
21Congress has already considered steps to regulate the ﬂow of AD/HD information in the school setting. Its
work can provide a valuable model for potential regulation in other areas.
The core characteristics of AD/HD—inattention, hyperactivity, and impulsivity—pose tremendous problems
for teachers. In a typical classroom, students are expected to sit at their desks each day for hours and
absorb—usually passively—the information communicated by the teacher at the front of the room. Even
under the best of circumstances, completing the curriculum and teaching children to behave properly are
demanding tasks for teachers.79 But with shrinking budgets, teachers have to manage increasingly larger
classes that produce more distractions and permit less ﬂexibility.80 In such a setting, one unruly student can
cause complete chaos.81 When a child with AD/HD ﬁdgets with his hands or feet, talks with classmates at
inappropriate times, leaves his seat without permission, or blurts out answers when the teacher is speaking,
it can be very disruptive to classroom instruction and disturb the educational process for all children.
Psychostimulant medications, however, oﬀer the teacher an easy way to make a child compliant. They make
children “sit down, shut up, keep still, and pay attention.”82 Teachers who are overwhelmed will sometimes
suggest to parents that their child suﬀers from AD/HD because they know that such a diagnosis usually
results in medication, and they do not see any other way of controlling the student. In some cases, teachers
are willing to take this radical step even if the teacher is not familiar with the intricacies of the diagnosis or
the student does not present any of the symptoms of the disorder. And when this technique proves successful
79DuPaul and Stoner 139.
80Diller 90.
81Michele Meyer, “Should Your Child Really be on Ritalin?” Better Homes and Gardens, September 1, 2003, p. 284.
82Eberstadt, supra note 19.
22and teachers see tangible results in the classroom, this makes them more likely to mention AD/HD to the
parents of other children who are disruptive.83
Large and unruly classes are not the only problem. Outcome-based educational systems also place enormous
demands on teachers. Such systems are based on the notion that every student “can and should be brought”
to perform at some minimal standard in the curriculum.84 This notion derives, in turn, from the egalitarian
view that all children are entitled to an equally eﬀective education at the expense of the public. Once a school
district adopts an outcome-based educational system, however, teachers cannot simply pass uncooperative
and inattentive students on to the next grade at the end of the school year—a practice known as “social
promotion.” Under outcome-based programs, teachers become directly accountable for the performance of
their students in the classroom. They therefore become desperate to ﬁnd ways to enable students to perform
at the mandated level.85 The AD/HD diagnosis, and the medication that often comes with it, is a powerful
lure to teachers in such a setting.86
The increasing willingness of teachers to consider and talk about AD/HD also derives from the fact that
there has been greater awareness about child and adolescent mental illness in recent years. As educational
professionals—both teachers and administrators—learn more about AD/HD and become more at ease with
83As Ken Livingston has written, “[W]hen it is diﬃcult or inconvenient to change the environment, we do not think twice
about changing the brain of the person who has to live in it.” Livingston, supra note 2.
84Id.
85Id.
86Livingston provides some empirical data regarding this phenomenon. He documents how, throughout the United States,
the increase in the number of AD/HD referrals closely tracks the adoption of outcome-based educational systems and notes
how states with these systems seem to have higher levels of Ritalin consumption than states without them. He points out that
the diﬀerence is small, amounting to only approximately.3 grams of Ritalin per 100 population. He notes, however, that this
diﬀerence is statistically signiﬁcant. Id.
23the lexicon of mental health, they become more willing to talk with parents about subjects that, years
ago, would have been “farmed out” to other, medically-trained professionals. As one writer has suggested,
teachers are increasingly seeing themselves not only as educators but as therapists as well.87
However, these factors—larger classes, outcome-based educational systems, and greater awareness of mental
illness in children—are only part of the story. Even if a teacher or school administrator is inclined to discuss
AD/HD and provide information about the disorder, it is essential to understand that a teacher’s provision
of information about AD/HD has little eﬀect by itself. It is the combination with another factor—namely,
the willingness and eagerness of parents to receive this information—that creates the problem. For a variety
of reasons, parents are often unusually receptive when a teacher provides information about AD/HD. First,
parents are hopeful that the medication that comes with the diagnosis will improve their child’s poor self-
esteem and conﬁdence.88 For children who may be borderline-AD/HD and who exhibit many of the disorder’s
symptoms, school is not an easy place to be, either academically or socially. Many of these children experience
demoralization and poor self-esteem on a regular basis. For a parent, it is a horrible thing to have to observe
87Id. Commentators have also suggested that teachers have been pushed by school administrators to have children labeled
as aﬄicted with AD/HD. The reason for this, or so the theory goes, is that schools can get extra dollars in special education
money for each child with AD/HD. But this is ridiculous for a number of reasons. First and foremost, it is diﬃcult to imagine
school administrators approaching teachers and asking them to label students with AD/HD for the purpose of raising money
for the district. Schools are short of money, but that they would propose branding a student with a potentially stigmatizing
label to raise a few extra dollars is simply absurd. Second, as Bruce Hunter, public aﬀairs director at the American Association
of School Administrators, has said, “any grant payments were too low, given the cost of providing special education, to push
schools to boost the number of AD/HD kids.” Quoted in John Merlloe, “Public Schools: Pushing Drugs?” Investor’s Business
Daily, October 16, 1997. Third, in recent years, the ﬁnancial incentive to label children with AD/HD has been removed.
Judith E. Heumann, former Assistant Secretary for Special Education and Rehabilitative Services at the U.S. Department of
Education, said the following in this regard: “Increasing the number of children who take behavioral drugs will not increase the
size of a school district’s IDEA [Individuals with Disabilities Education Act] grant. IDEA funds are distributed to states and
school districts based on the size of the jurisdiction’s population of school age children and the relative number of those children
who live in poverty. Funds are not distributed based on the number of children identiﬁed as disabled and in need of special
education. There was a formula change that, in fact, took place in 1997 when we reauthorized the IDEA so that incentive
would be removed.” Statement of Judith E. Heumann, Assistant Secretary for Special Education and Rehabilitative Services,
U.S. Department of Education, Washington, D.C., in Behavioral Drugs in Schools: Questions and Concerns. Hearing Before
the Subcommittee on Oversight and Investigations of the Committee on Education and the Workforce, United States House
of Representatives, 106th Congress, September 29, 2000 (Washington, D.C.: U.S. Government Printing Oﬃce, 2000), online at
http://commdocs.house.gov/committees/edu.
88Singh 20-21.
24a child constantly depressed and sad. Therefore, if there exists a way to combat such problems, it is easy to
see why a parent would jump at the opportunity. Ilina Singh, using a ﬁctional child named Tom, describes
the chain of events that many parents imagine:
Ritalin combats deﬁciencies in the brain, allowing a child, Tom, to control his impulsiveness.
Now Tom can sit still in his chair at school, which allows him to take good notes and copy
down his homework assignments. His teacher begins to praise his improved work, and other
students begin to notice that Tom is really not as wild as he once was. Those students
now approach Tom, wanting to be his friend. The combined eﬀects of success at school,
the teacher’s praise, and his peers’ sociability provide Tom with newfound conﬁdence and
self-esteem.89
And it is not only the child’s poor self-esteem that the parents are worried about. They are also concerned
about their own demoralization. Raising a child who has persistent educational and attentional diﬃculties
is not an easy task. Internally, parents are often exasperated with their out-of-control children and blame
themselves for their child’s shortcomings. Externally, they constantly face accusations, whether express or
implied, that they are inadequate and uncaring.90 Under such trying circumstances, when a teacher comes
along and says that there may be a biological explanation for their child’s problems, parents are almost
always willing to listen such a suggestion. If brain chemistry is to blame, not only are the parents not at
fault; they can also ensure that their child receives appropriate treatment with medication. This, then, is
the second reason that parents are willing to listen to teachers: an AD/HD diagnosis and medication often
makes parents feel better about themselves.
Third, parents are generally impressionable to the comments that a teacher makes. Students spend a great
90Id. at 1-2. It is not surprising, then, that rates of parental stress are higher among parents of AD/HD children. Id. at 27.
25deal of their time at school, and the teachers serve in loco parentis. Furthermore, in modern American society,
it is often the case that both parents work. They are not able to spend much time with their children, and
they often look to schools and teachers to ﬁll the gap. Therefore, when a teacher makes a comment about
AD/HD to a parent, very often the parent is inclined to accept the teacher’s words at face value.
Fourth, and most importantly, parents are willing to accept information about the disorder because they
know that an AD/HD diagnosis and medication might provide their child with an advantage over other
students. We live in an increasingly competitive age, where parents strive to get their children into the
“right” nursery schools and spots at the most competitive colleges are ﬁercely fought over. Parents look for
anything that will give their child an edge over others. If science, in the form of new medications, oﬀers a
way to boost concentration and thereby improve performance, parents often ask why their kids should not
have this advantage. Thomas Armstrong best summarized the appeal of medication in his book The Myth
of the A.D.D. Child. He writes, “Many middle and upper-middle class parents see Ritalin and related drugs
almost as ‘cognitive steroids’ that can be used to help their kids focus on their schoolwork better than the
next kid.”91 Given this belief, it is not surprising that psychostimulants are most often prescribed in middle-
and upper-class schools, where performance demands are often strongest.92,93
91Cited in Eberstadt, supra note 19; Thomas Armstrong, The Myth of the A.D.D. Child (New York: Dutton, 1995). Although
parents hope to increase a student’s performance through medication, it may very well have the opposite eﬀect and prevent
the student from learning. Katherine Bryson, a State Representative in the Utah House of Representatives, relates: “I taught
school myself in California back in the mid 1970s. I had kids who were in my little ﬁfth grade class who were going out and
being medicated at noon and coming back in the classroom, and they were literally what I would term zombies for the rest of
the afternoon. Now, that was not a situation where I could help meet their educational needs. They were in a position where
they were not receptive. They could not be receptive, and it was a wonderful classroom. They were now compliant. Yes, they
were compliant, but were they teachable and were they learning anything? I do not believe so.” Statement of Hon. Katherine
Bryson, State Representative, Utah House of Representatives, in Protecting Children, supra note 4.
92This is a form of “cosmetic psychopharmacology.” Cosmetic psychopharmacology is the use of psychotropic medication
for non-therapeutic enhancement. The phrase was coined by Peter Kramer in his inﬂuential book, Listening to Prozac. Peter
Kramer, Listening to Prozac (New York: Viking, 1993), p. 273.
93It should be pointed out that the AD/HD diagnosis not only oﬀers children a way to boost their concentration; it also
gives them access to special resources at school. The beneﬁt most commonly cited is extra time on tests and standardized
examinations. The number of people granted an unlimited-time allowance for the SAT doubled between 1991 and 1996, from
17,000 to about 35,000. There have been similar increases with regard to the administration of graduate-level exams. In the
1996-1997 academic year, for example, 160 students received special accommodations when taking the Law School Admission
Test (LSAT), compared with only 10 students ﬁve years earlier. Diller 163. With the beneﬁts that can come from extra time or
26With the readiness of the teachers to provide this information and the willingness of the parents to receive it,
it should not be surprising that information about AD/HD is free-ﬂowing. There is, however, a strong (and
perhaps obvious) policy justiﬁcation for regulating the ﬂow of this information—namely, that those who are
providing the information (the teachers) are probably not the ones best qualiﬁed to be doing so. Although
teachers spend a great deal of time with children in the classroom and are frequently the ﬁrst to recognize
learning and/or behavioral problems, the basic and inescapable fact is that teachers are not doctors, and
they are not diagnosticians.94 They usually know little, if anything, about AD/HD, its symptoms, and forms
of treatment.95 Furthermore, they are not skilled in understanding the normal range of behaviors, despite
all their training and their continual exposure to a large and heterogeneous group of students.96 In the case
of AD/HD, such an understanding is essential, since AD/HD is a disorder in which many common behaviors
are included among the symptoms. Teachers, for example, often do not understand that, as one doctor points
out, “there are some normal behavioral traits of stubbornness, shyness, and loudness that are annoying but
that are not abnormal and do not deserve to be treated with medication.”97 It is the diagnosis of a trained
physician that should be paramount in determining whether a child is suﬀering from the disorder.
special accommodation on such high stakes exams, it is hardly surprising that more and more parents have been visiting their
children’s doctors demanding some sort of oﬃcial diagnosis. Eberstadt, supra note 19. As Mary Eberstadt relates, this is, in a
way, “aﬃrmative action for aﬄuent white people.” Id.
94Written Statement of the National Mental Health Association, in Protecting Children, supra note 4; testimony of E. Clarke
Ross, CEO of Children and Adults with Attention-Deﬁcit/Hyperactivity Disorder (CHADD), in Attention-Deﬁcit/Hyperactivity
Disorder, supra note 11.
95Congressman Michael Castle (R-DE) perhaps explained the problem best when he wrote, “We have enough trouble training
our teachers to teach math, English, or whatever the subject matter may be.” Statement of Congressman Michael Castle, in
Protecting Children, supra note 4.
96Statement of William Carey, supra note 4. This should not be surprising. Even doctors with tremendous expertise in
psychiatry over many years have diﬃculty easily distinguishing the normal from the abnormal. As Dr. William Carey has
said, “I have been studying this for 35 years, and I see a great deal of overdiagnosis of normal behavior as being such things as
AD/HD.” Id.
97Id.
27Despite their lack of medical training, teachers and school administrators have not been shy about providing
parents with information about AD/HD. In some cases, they have even gone so far as to diagnose children
with the disorder and have told parents that their children would not be allowed to attend school and
continue in their classes if they did not take medication.98 And in several of these cases, not only has the
student been expelled after the parents failed to comply with the school’s order; school oﬃcials also asked
state child protective agencies to judge the parents unﬁt on charges of medical neglect. The experience of
Patricia Weathers,99 a mother in Mill Brook, New York, provides an illustration:
Near the end of the ﬁrst grade, the school principal took me into her oﬃce and said that
unless I agreed to put Michael [Patricia’s son] on psychiatric drugs the school would transfer
him to a special education center for children with behavior problems. As a parent, I felt
extremely pressured by the school’s staﬀ at this point. The teacher, school psychologist,
and principal were all telling me that putting my son on drugs was the right thing to do.
[Weathers then followed the school’s advice and put her son on Ritalin].
I didn’t notice any diﬀerence at ﬁrst [with the Ritalin], but eventually I began getting
reports that Michael was not socializing with other kids, and that he was withdrawn. This
was completely out of character for Michael who was normally very social and outgoing. It
got worse. When Michael was in the third grade, my grandmother saw Michael just standing
by himself at the far corner of the playground staring at his feet. I also began receiving
reports that Michael had started chewing on things, pencils, erasers, and paper, even his
clothing. His behavior was getting more and more bizarre.
Instead of recognizing the eﬀects the drugs were having on my son, the school’s psychologist
claimed Michael now had a “social anxiety disorder and needed to see a psychiatrist.” She
immediately produced the name and the number of the psychiatrist I was to call. The
psychiatrist talked to Michael for ﬁfteen minutes and, again, with the aid of the school
reports, diagnosed him with social anxiety disorder. She handed me a prescription for an
antidepressant and told me it was a wonder drug for kids. On October 5, 1999, Michael
started taking the antidepressant. Shortly afterwards, he told his teacher he was hearing a
male voice in his head telling him to do bad things. [Soon after, Weathers took her son oﬀ
the drugs].
98Ilina Singh found that mothers were often told by teachers that their children had AD/HD even before the children had
been formally tested. Singh 138.
99As mentioned above, Patricia Weathers is also President of Parents for Label and Drug Free Education.
28This led to a downward chain of events, which culminated in the school calling Child Pro-
tective Services on my husband and I, and charging us with medical neglect. The charge was
for failing to give Michael the necessary medication and failure to follow the psychiatrist’s
advice of hospitalization. The only reason my son was not removed from my custody that
day was that I had obtained an independent psychological evaluation in which the psychol-
ogist stated that Michael did not require hospitalization. If it were not for this, he would
have been taken from our home.100
Such coercive tactics by teachers and educational administrators have aﬀected thousands of families across
the country.101 They have even aﬀected Neil Bush, brother of President George W. Bush, who faced pressure
by a Houston school to medicate his son Pierce with Ritalin.102
Dangerous situations such as these compelled the federal government to act, and Congress obliged with
H.R. 1170, the Child Medication Safety Act of 2003. The bill passed the House of Representatives in May
2003 and was then sent to the Senate, where it languished in committee and died.103 The particular goal
of the legislation was to require states to establish policies and procedures that prohibited school teachers
and administrators from forcing parents to medicate their children as a prerequisite for the child attending
school.104 This prohibition is stated in Section 2(a) of the bill. A more general goal was to regulate the
provision of information about AD/HD. This is clear from the bill’s legislative history. House Report 108-121,
which accompanies H.R. 1170, cites, in its explanation of the Child Medication Safety Act and its purposes,
testimony by Dr. William Carey before the Subcommittee on Education Reform. Dr. Carey stated:
101On August 7, 2002, The New York Post told Michael’s story. Within a few days of publication of the article, over 65 parents
came forward to describe how their school districts had used various methods of coercion and intimidation to strong-arm them
into drugging their children. See Statement of Patricia Weathers in Attention-Deﬁcit/Hyperactivity Disorder, supra note 11.
102Written statement by Dr. Karen Eﬀrem, in Ritalin Use Among Youth, supra note 9.
103The bill passed the House by a vote of 425 to 1.
104Several states had already taken a similar step. In Utah, for example, a bill was introduced to prohibit school teachers and
administrators from recommending that a child use psychotropic drugs. See Utah H.B. 123 (2002).
29In the last two decades the United States has experienced a great increase in the diagnosis
of Attention Deﬁcit Hyperactivity Disorder (ADHD) and its treatment with stimulants.
Not only child health professionals but now also a wide variety of unqualiﬁed persons, such
as preschool teachers and acquaintances, are freely oﬀering the diagnosis and conﬁdently
urging parents to accept their judgment and obtain drug treatment, such as methylphenidate
(Ritalin), for the child... . This chaotic situation urgently requires intervention at several
levels, including the Federal government.105
Although the Child Medication Safety Act was well intentioned, it was ﬂawed because it was overinclusive.
The legislation provided major disincentives for open communication between school personnel and parents
on a whole host of issues, not just on information relating to whether a child has AD/HD.106 As I have
emphasized in the foregoing discussion, teachers should not take on the role of doctor and eﬀectively diagnose
a student with AD/HD. Teachers, however, do serve important functions when it comes to the treatment
of AD/HD—in particular, they serve as valuable conduits for information. For example, when a child is
already on medication, teachers provide doctors with information on the medication’s eﬀectiveness in the
school setting.107 This information, in turn, is used to determine the proper dose of medication.108 The Child
Medication Safety Act, however, would have impeded teachers when carrying out such a function because
it would have made teachers who had legitimate health concerns about students reluctant to communicate
those concerns for fear of violating the strictures of the statute.
The proposed legislation did attempt to accommodate legitimate teacher interventions. It provided a rule
of construction in Section 2(b), which read as follows:
106Written statement of Audrey Spolarich, Chair, Coalition for Children’s Health, in Protecting Children, supra note 4. Using
the vocabulary of constitutional law, the legislation was not narrowly tailored. The means were not well suited to the ends.
107Russell A. Barkley, “Foreward,” in DuPaul and Stoner x-xi.
108The increasing use of medications that only need to be taken once a day—medications such as Concerta, Metadate CD,
Adderall XR, Ritalin LA, and Strattera—has reduced the involvement of school teachers and staﬀ in the administration of
medications. Nevertheless, school personnel are still relied upon heavily in many instances. Id.
30Nothing in subsection (a) shall be construed to create a Federal prohibition against teach-
ers and other school personnel consulting or sharing classroom-based observations with
parents or guardians regarding a student’s academic performance or behavior in the class-
room or school, or regarding the need for evaluation for special education or related ser-
vices under section 612(a)(3) of the Individuals with Disabilities Education Act (20 U.S.C.
1412(a)(3)).109
It is diﬃcult to see, however, how these words would have any real eﬀect in actual practice. Teachers, never
certain whether their comments about a student would fall under the general prohibition provided for in
Section 2(a) of the law or under the more permissive rule of construction of Section 2(b), would, in all
likelihood, refrain from commenting at all about a student. The bill, therefore, would have resulted in a
system where teachers would be afraid to engage the parents and express themselves openly.110 Ultimately,
it would have made teachers too cautious to assist those children who truly need their help.111
Thus, the Child Medication Safety Act was not well targeted to the ills it was designed to address. Perhaps
this is one of the reasons that it died in the Senate. Should Congress decide to take up this issue again in
future years, it will need to put in place a better mechanism—one that ensures both that parents are not
coerced into putting their kids on psychotropic drugs and that teachers have an outlet should they need
to communicate their concerns about a child. With the Child Medication Safety Act, Congress addressed
the former concern, but not the latter. Despite the bill’s shortcomings, it is valuable as a model because it
shows that regulation is indeed possible when it comes to the provision of information about a disease or
condition. Furthermore, the lessons learned with the Child Medication Safety Act can perhaps be applied
in future legislation designed to regulate the other sources of information about AD/HD.
110Statement of Lance Clawson, in Protecting Children, supra note 4.
111Written statement of Audrey Spolarich, supra note 106. These problems mean that the bill, even if passed, might have faced
First Amendment challenges on vagueness grounds. The Supreme Court has ruled unconstitutional laws that are so vaguely
written “that persons of average intelligence must guess at their meaning and application.” See “Free Speech,” online at the
web site of the Electronic Privacy Information Center (http://www.epic.org/ free speech). Vague laws “chill” speech because
people subject to such laws often keep silent out of fear that their intended conduct might be illegal. Id. The Child Medication
Safety Act would almost certainly face challenges for “chilling” speech.
31IV. Media (Internet and Direct-to-Consumer Advertising)
We now turn our attention to another major source of information about AD/HD: the media. Unlike
the educational system, which focuses on instances of AD/HD in children, media sources provide relevant
information about the disorder to children and adults alike. Discussions about “the media,” however, are
somewhat ambiguous, as “the media” comprises a number of diﬀerent components, each of which provides
information about the disorder. Television, newspapers, and magazines all carry news reports and feature
presentations that describe the prevalence of AD/HD in American society and the people who have suﬀered
from the side eﬀects of medication.112 There are also countless books and articles on the subject, written by
AD/HD specialists, as well as by those who suﬀer from the disorder and who feel that they have something
to share.113 In this article, however, I shall focus on two areas of the media that have had a disproportionate
impact on the dissemination of information about AD/HD: the Internet and direct-to-consumer (DTC)
advertising. I will look at these areas in turn.
The Internet
112Diller says that these news reports are overly formulaic, as well as oversimpliﬁed, especially on television. He writes:
The usual formula is to begin with the reporter commenting on the “new” diagnosis of [AD/HD] and the explosive growth
in Ritalin use, followed by the provocative question: Are children being overdrugged in our classrooms? Two families will be
presented: one with a child whose “life was saved” by Ritalin, contrasted with another whose child experienced intolerable side
eﬀects or underwent an undesirable personality change on Ritalin. Next the “experts” appear in front of impressively ﬁlled
bookshelves in their oﬃces, or striding down a hospital corridor. Each expert (usually two) gets about 15-20 seconds for a
statement. Then the camera cuts back to the children—one happily playing in the schoolyard, apparently cured of his malady,
the other at home, lovingly protected by his parents from the vagaries of medical science. The segment closes with the reporter
solemnly intoning, “ADD and Ritalin—cure or curse? Make sure you check with your doctor.” Finally, the news anchor may
ad-lib a remark to colleagues in the studio that may reﬂect insensitivity, misunderstanding, or worse.
Diller 137.
113Texts in the second category include Benjamin Polis’s wonderful Only a Mother Could Love Him, which oﬀers the youth
perspective on the disease. See Benjamin Polis, Only a Mother Could Love Him (New York: Ballantine Books, 2004). There is
also a text by Chris A. Zeigler Dendy and Alex Zeigler entitled A Bird’s Eye View of Life With ADD and AD/HD. See Chris
A. Zeigler Dendy and Alex Zeigler, A Bird’s Eye View of Life With ADD and AD/HD (Cedar Bluﬀ, Alabama: Cherish the
Children, 2003). The authors spoke with 12 teenagers aﬄicted with AD/HD who told about their experiences and provided
advice. It should be noted, however, that books written by suﬀerers, especially adolescent suﬀerers, are quite rare. This is a
shame, as some doctors often are mistaken about the true nature of the disease. Polis decided to write his book after hearing
an expert on “60 Minutes” in Australia explain why kids with AD/HD behave as they do. Polis said, “This guy was describing
the way us kids felt. And I thought, ‘This guy doesn’t know.’ I thought he was wrong.” Laurie Tarkan, “Attention Disorder
Advice, by One Who Knows,” The New York Times, August 26, 2003.
32Use of the Internet to ﬁnd information regarding illness has grown tremendously in recent years. One survey
assessing the sources of information that people use to ﬁnd out about conditions and treatments found that
79.2% of respondents turned to general health sites on the Internet.114 In the case of AD/HD, however,
this willingness to use the Internet causes problems. There is so much information online about the disorder
that anyone perusing the various AD/HD web sites is likely to be overwhelmed by the glut of information.
Parents looking for a summer camp with a supportive environment for children with AD/HD or ones worried
about their AD/HD kids behind the wheel of a car can ﬁnd web sites in Japanese, Dutch, and English to
address their needs and concerns. There are sites that say that nearly all people have AD/HD, and others
that say that AD/HD is a fraudulent medical diagnosis and that no one has the disease. There are sites that
cater to Christian AD/HD suﬀerers, as well as ones geared toward women, teens, families, and preschoolers.
There are sites exhibiting artwork created by those aﬄicted with AD/HD and sites that describe Chinese
herbal treatments for the disorder. There are countless reports, studies, and pamphlets to be found online.
Furthermore, the Internet is a popular gathering place for individuals involved with AD/HD. There are
hundreds of AOL chat groups devoted to the condition.115 For people navigating this mass of information,
it is not at all clear where to look for the best and most up-to-date information on the disorder.
The greatest cause for concern, however, is the fact that little of the information presented seems to be
completely objective. Most of the web sites seem to be geared toward one point of view or another. In
general terms, most AD/HD sites on the Internet seem to fall into one of two categories. First, there are
the obvious zealots and partisans. These are the web sites created by individuals or organizations that
114See Carol Rothkopf, “The DTC Information Process,” presentation at an FDA public meeting on direct-to-consumer
promotion, September 22 and 23, 2003, online at http://www.fda.gov/cder/ddmac/P1Rothkopf/index.htm.
115Diller 132-133. On June 29, 2004, I entered “ADHD” into the Internet search engine “Google.” 2,130,000 websites were
listed. On September 6, 2004, I did the same search, and 2,170,000 sites were listed. With over two million diﬀerent web sites
listed, the fact that 40,000 new sites were added over a two-month span hardly makes much of a diﬀerence.
33make it clear that they harbor a particular point of view about AD/HD and about how (and whether) it
should be treated. Although some of the web sites in this category strongly support the AD/HD diagnosis,
most are ones that openly denounce AD/HD and the drugs used to treat the disorder. Adhdfraud.com and
ritalinfraud.com are two web sites, for example, that are open in their disdain for the disorder. (Indeed,
from the very names of these web sites, their position is obvious.) Such sites are plentiful, yet they do not
pose all that much of a danger, because a person who is searching for objective information and comes upon
one of these sites understands immediately that the creators of the site adhere to a particular position.116
Much more alarming are the web sites that fall into the second category, sites created by those whom I refer
to as the “hidden zealots.” These are the web sites that put themselves forward as places to obtain objective
information on AD/HD yet have a hidden agenda. The most obvious examples of web sites in this category
are those set up and run by the pharmaceutical companies. Such sites are usually presented as places where
one can ﬁnd clear and unbiased information about AD/HD. The pharmaceutical companies, however, have
a vested interest in making people buy their medications, so their presentation of facts about the disorder is
subtly geared toward that end. For example, the address of one popular pharmaceutical company-sponsored
web site is the seemingly innocuous “ADHDinfo.com.” When one goes to this site and clicks on the link
to the page discussing “Responsible Treatment,” the ﬁrst thing that appears on the computer screen is a
discussion about the use of psychostimulant medications.117
Even more dangerous, though, is the web site of an organization called Children and Adults with Attention-
Deﬁcit/Hyperactivity Disorder, or CHADD. Founded in 1987, CHADD is by far the largest organization
116What is ironic, though, is that these organizations that disfavor the AD/HD diagnosis make it more visible by their eﬀorts
in creating web sites.
117As of January 16, 2005.
34devoted to AD/HD. It has become the “voice” of the disorder in recent years, and it is for this reason that I
devote considerable discussion to it here.118 CHADD puts itself forward as “the nation’s leading non-proﬁt
organization serving individuals with Attention-Deﬁcit/Hyperactivity Disorder (AD/HD).”119 Although the
group organizes lectures, operates chat and discussion boards, issues an electronic newsletter, and produces
a bi-monthly magazine (entitled Attention!), the centerpiece of its eﬀorts is its “exceedingly active” web site,
www.chadd.org, where online information sheets, medical resources, policy papers, and items for sale can all
be found.120
CHADD, however, is not as objective as it makes itself out to be. It consistently portrays AD/HD as a
neurobiological disorder and is biased in favor of the use of medication to treat the condition.121 Furthermore,
it has a shameful history of taking money from the drug companies. This came to light in 1995 after the
group launched a campaign to have the DEA deregulate the prescription of methylphenidate by reclassifying
it as a Schedule III drug under the CSA. CHADD publicly cited a number of reasons for its petition:
1) Since the DEA is required to approve an annual production quota (APQ) for
methylphenidate, there always looms the possibility of a drug shortage if the demand grows
in a given year and exceeds the supply.122
118Diller 131. CHADD is also a lobbying organization with tremendous inﬂuence and power. When the IDEA was ﬁrst being
considered in 1990, there was a debate about whether to include AD/HD as one of the disabilities that would qualify people
for services. CHADD and ADDA (another AD/HD “self-help” organization) lobbied hard for its inclusion. Phyllis McClure,
who for 24 years represented the NAACP Legal Defense and Education Fund (which opposed the inclusion of AD/HD in the
IDEA), remembers the pressure exerted by the groups during the IDEA drafting process. Their lobbying of her could almost
be considered harassment, she told Diller: “They followed me all the way out to the airport once. They just wouldn’t let go.”
Diller 149-150. When the IDEA drafters ultimately decided to exclude AD/HD, CHADD, in coordination with other groups,
generated over 4000 letters to members of Congress, key Congressional committees, and the Department of Education. These
groups also used their inﬂuence to persuade senators and congressmen to exert pressure on the Department of Education to
reconsider the inclusion of AD/HD in the IDEA. These eﬀorts paid oﬀ. In September 1991, the Department of Education issued
a Policy Clariﬁcation Memorandum ordering schools to include AD/HD as a covered disability under the IDEA. Diller 150;
Eberstadt, supra note 19.
119See www.chadd.org (last checked February 18, 2005).
120Id. When one types “ADHD” into the online search engine Google, CHADD’s web site comes up ﬁrst.
121For example, one fundraising letter from 1997 urged readers “to [ﬁght] these battles of misinformation, innuendo, ignorance
and outright hostility toward CHADD and adults who have a neurobiological disorder.” Cited in Eberstadt, supra note 19.
352) Deregulation will aid doctors by allowing them to dispense prescriptions simply by call-
ing the pharmacy. Under the existing CSA regime, prescriptions for psychostimulants are
required to be written in triplicate, and reﬁlls cannot be dispensed via telephone. The pro-
posed change will also aid patients, who are inconvenienced because they have to visit their
doctors every time their prescriptions run out.
3) Methylphenidate’s Schedule II classiﬁcation stigmatizes patients. The authors of Driven
to Distraction, a well-known AD/HD treatise, claimed that one of the most common prob-
lems in treating the disorder is that “some pharmacists, in their attempt to comply with
federal regulations, make consumers [of methylphenidate] feel as though they are obtaining
illicit drugs.”123
Although these were all valid justiﬁcations, it was soon revealed that something else was behind CHADD’s
eﬀorts at deregulation. While CHADD awaited the DEA’s decision, a television documentary revealed that
Ciba-Geigy (now called Novartis), the pharmaceutical company that manufactures Ritalin, had contributed
$748,000 to CHADD from 1991 to 1994. Moreover, the documentary reported, CHADD oﬃcials had never
disclosed the existence of this money or its source to the organization’s own members or to the public.124
This revelation gave rise to concerns about whether pharmaceutical companies were unduly inﬂuencing
CHADD’s agenda.125 Deregulation would obviously be immensely valuable for these companies. Even
today, however, CHADD refuses to admit that Ciba-Geigy’s ﬁnancial contributions were related the DEA
deregulation petition.
The DEA eventually took action on the petition. It issued a scathing report that stated the following:
It has recently come to the attention of the DEA that Ciba-Geigy, the manufacturer of the
methylphenidate product marketed under the brand name Ritalin, contributed $748,000
to CHADD from 1991 to 1994. The DEA has concerns that the depth of the ﬁnancial
relationship with the manufacturer was not well known to the public, including CHADD
members that have relied upon CHADD for guidance as it pertains to the diagnosis and
treatment of their children. [Ciba-Geigy] stands to beneﬁt from a change in scheduling of
methylphenidate.126
124Anne Manne, “Cries unheard,” Arena Magazine, April 1, 2003, p. 47.
125Diller 39-40.
36The DEA also noted that “of particular concern” was the fact that most of the AD/HD material prepared
for public consumption by CHADD did not address the potential or actual abuse of Ritalin.127 Instead,
the drug was portrayed “as a benign, mild substance that is not associated with abuse or any serious side
eﬀects.”128 The DEA made clear, however, that in reality “there is an abundance of scientiﬁc literature
which indicates that methylphenidate shares the same abuse potential as other Schedule II stimulants.”129
In the years since this scandal, CHADD has attempted to rehabilitate its image.130 Yet charges of collusion
with the pharmaceutical industry continue to linger and aﬀect CHADD’s credibility. Critics not only continue
to cite the deregulation petition of the mid-1990s, which is seen as a betrayal of those aﬄicted with AD/HD;
they point to the continued appearance of impropriety by the organization. Note the following exchange
between E. Clarke Ross, CHADD’s CEO, and Congressman Dan Burton, during a September 2002 hearing
before Congress:
127“Methylphenidate: A Background Paper,” supra note 37.
128Id.
129Id.
130CHADD’s rehabilitation eﬀorts have proved diﬃcult, as the organization continues to receive substantial funds from the
pharmaceutical industry. As of August 2002, pharmaceutical ﬁnancial support constituted 18% of CHADD’s budget. Testimony
of E. Clarke Ross, supra note 94. CHADD oﬃcials, however, have attempted to justify the organization’s use of pharmaceutical
funds. As one oﬃcial has said, “The organization and the diagnosis itself is not one that is real popular among people who
want to donate money. They want to donate to the heart association, et cetera, so getting funds is a little more diﬃcult
than, say, other nonproﬁt organizations that work for kids. However, when we do accept pharmaceutical money, it is accepted
and a contract is signed which says in no way will they have anything to do with, any say with how the organization runs
the projects. ...And CHADD solely directs the projects of the organization.” Statement of Mary Robertson, Past President
of CHADD, in Ritalin Use Among Youth, supra note 9. Even the drug companies have tried to step in to help CHADD
rehabilitate its image. Novartis, for example, said that although it had provided (in the years since the scandal) unrestricted
educational grants to CHADD for projects such as a public service announcement on AD/HD and the translation of some
AD/HD literature into Spanish, it believed that such grants were appropriate. “Novartis believes that comprehensive care for
all patient populations includes education and support as well as medication. Novartis is proud to help CHADD and other
credible third-parties that provide valuable information to many people.” Cited in Frontline: “AD/HD Lawsuits,” online at
http://www.pbs.org/wgbh/pages/frontline/shows/medicating/backlash/lawsuits.html. Novartis’s words, at ﬁrst glance, make
sense. It must be remembered, however, that drug company support of CHADD is diﬀerent from drug company support
of the American Diabetes Foundation or the American Cancer Society. The reason: psychostimulants are Schedule II—and
hence potentially highly addictive—drugs regulated under the CSA. See Statement of Peter Breggin, in “Medicating Kids: The
Business of AD/HD,” online at http://www.pbs.org/ wgbh/pages/frontline/shows/medicating/experts/business.html.
37Congressman Burton: I would also like to end by saying, Mr. Ross, I do—we had what
was called the “Keating Five” here in Washington. We had ﬁve Senators that met with
Mr. Keating on the savings and loan crisis, and I don’t believe any of those Senators really
intentionally did anything wrong, but the appearance of impropriety was very great and
they got a heck of a lot of bad publicity when the savings and loan debacle took place. And
for you to get hundreds of thousands of dollars from Novartis, which manufactures Ritalin,
and your organization does advocate that children should use that, it gives the appearance—
Mr. Ross. We do not advocate any brand drug.
Mr. Burton. Well, I—
Mr. Ross. We advocate a multimodal treatment which may include medication—
Mr. Burton. I understand.
Mr. Ross [continuing]. And the products are never discussed.
Mr. Burton. Regardless—I understand, but the appearance is that they’re feeding you to
deal with this problem in that way, and I would just suggest, if there was a better way to
fund your organization, even if it is only 18 percent, it would be helpful, because if you were
in the U.S. Senate or the House and that happened, you would have a heck of a problem.131
Even putting aside, though, CHADD’s credibility problems and its conﬂicts of interest, the information
actually provided on the organization’s web site shows that CHADD is far from a clearinghouse of objective
information. CHADD claims on its web site (as Clarke Ross suggested in his Congressional testimony cited
above) that it advocates a multimodal approach to the treatment of AD/HD, including the use of behavior
management techniques, individual and family counseling, and medication when required. But a closer
look at the web site makes one question whether CHADD really does support such treatment. There is a
subtle, but clear, emphasis on medication use throughout the organization’s web site. For example, when I
recently132 looked at the site’s home page, I was immediately confronted with a box at the top of the screen
entitled “What’s New?” The ﬁrst two items listed in the box related to the use of certain medications—
Adderall XR (a psychostimulant) and antidepressants. Similarly, at the bottom of the same page, there is
an oﬀer for a “discount prescription card.”133 As Lawrence Diller says, “CHADD’s leadership will dispute
this [emphasis on medication], and its literature seems to advocate a multimodal model of treatment—but
132On February 25, 2005.
133See www.chadd.org.
38close reading will reveal an emphasis on medication....”134
CHADD is the organization that, through its web site, is providing a great deal of information about AD/HD
to the general public. However, CHADD’s ties to the pharmaceutical industry and its advocacy of medication
are alarming. Is this the kind of organization that we want providing much of our information about a medical
disorder? The answer is clearly no.135 Therefore, it pays to ask the following question: Is there any way
to control CHADD and other similar “hidden zealot” organizations and regulate the information that they
release on their web sites? It is not clear that much can be done. Current First Amendment law gives
individuals and organizations great freedom to post what they want on the Internet. In 1997, in Reno v.
American Civil Liberties Union, the Supreme Court unanimously held that the Internet, a “unique and wholly
new medium of worldwide human communication,” was deserving of full First Amendment protection.136 In
an opinion written by Justice Stevens, the Court explained its reasons for such a holding:
Through the use of chat rooms, any person with a phone line can become a town crier with
a voice that resonates farther than it could from any soapbox. Through the use of Web
pages, mail exploders and newsgroups, the same individual can become a pamphleteer. As
the District Court found, “the content of the Internet is as diverse as human thought.” We
agree with its conclusion that our cases provide no basis for qualifying the level of First
Amendment scrutiny that should be applied to this medium.137
The result of the Court’s holding is that in any free speech issue relating to the Internet, established rules
and principles of First Amendment jurisprudence apply. If I was to post on a web site an article criticizing a
famous scholar, actor, or politician, I could not be sued for libel unless there was proof of “actual malice.”138
134Diller 130.
135Id. at 131-132. Diller relates that some parents, after attending a few CHADD meetings, have called him to ask if he
knows of an organization for families who do not want to give medication to their children with AD/HD. They feel that within
CHADD, there is little tolerance for those who are opposed to the use of medication. Diller 130.
136Reno v. American Civil Liberties Union, 521 U.S. 844, 850 (1997); see “Free Speech,” online at the web site of the
Electronic Privacy Information Center (http://www.epic.org/free speech).
138See New York Times Co. v. Sullivan, 376 U.S. 254 (1964); the web site of the First Amendment Center, online at
http://www.ﬁrstamendmentcenter.org.
39Similarly, speech that serves to educate, such as the speech of CHADD—speech that does not fall under
any of the well-known “exceptions” in First Amendment law, such as obscenity or “commercial speech”—is
entitled to the highest degree of First Amendment protection.139
However, even if free speech concerns limit the ability to regulate, the United States government does not
have to subsidize these groups in any way. The federal government, however, has continued to deal with
CHADD, for example, despite its checkered history. In August 2002, CHADD received a grant of $750,000
from the Centers for Disease Control and Prevention to establish and operate a National Resource Center
on AD/HD.140 CHADD has also beneﬁted from a Center for Mental Health Services $150,000 subcontract
with the American Institutes for Research “to conduct community forums and increase participation within
CHADD for the purposes of cultural competence and diversity promotion in order to better educate the
public about AD/HD and related childhood mental disorders.”141 In the future, the government should
refuse to award such grants and contracts. It is not clear that this would have much of a ﬁscal impact,
given the other sources of revenue—especially pharmaceutical company money—that these “hidden zealot”
organizations receive. But at least it would prevent these groups from putting the U.S. government “stamp
of approval” on its materials.
Direct-to-consumer (DTC) advertising
The other major source of information about AD/HD within the media is direct-to-consumer (DTC) adver-
139I have asserted throughout much of this paper that CHADD may in fact be something more than a mere “educator”
providing information to the AD/HD masses. I have stated that CHADD may also be “selling” a particular point of view about
AD/HD—that it is a biological disorder to be treated with medication. Even if this is true, it does not mean that CHADD’s
speech would be considered “commercial speech” for First Amendment purposes. CHADD’s speech is primarily educational.
The commercial overtones that taint many of the organization’s messages are incidental to the educational nature of the speech.
140Testimony of E. Clarke Ross, supra note 94.
141Id.
40tising.142 DTC advertising allows pharmaceutical manufacturers to present their products to mass audiences
through television, radio, print, and the mail. The use of these diﬀerent means of communication to market
drug products is important, given the ultra-competitive nature of the brand-name pharmaceutical industry
and the competition provided by generic substitutes.143
Just as people have been using the Internet more and more to ﬁnd information about diﬀerent conditions
and treatments, they are also increasingly using DTC advertisements to get their information. In 2002, 81%
of people surveyed said that they had seen or heard an advertisement for a prescription drug within the
previous three months.144 In 2005, that number has likely grown. The eﬀect of DTC advertising has been
so great that it would not be an exaggeration to say that it has, in many ways, transformed the way people
think about disease and medication. For example, as Stephen Ceccoli points out, many Americans, simply
as a result of DTC advertising, can recognize prescription drugs based on simple catch phrases or color
associations. They know AstraZeneca’s heartburn drug, Nexium, as the “purple pill” and Pﬁzer’s Viagra as
“the little blue pill.”145
In recent years, spending by pharmaceutical companies on product promotion and DTC advertising has
142Pharmaceutical manufacturers generally produce three kinds of DTC advertisements. First, “help-seeking” advertise-
ments mention an illness or a disorder but do not mention any drug by name. Such advertisements encourage people to
speak with their doctors about their condition. Second, “reminder” advertisements mention a particular drug but do not
mention what the drug is used for. Finally, “product claim” advertisements (the most common kind of DTC advertise-
ments) mention both a particular product and the condition the product is intended to treat. Ceccoli 155. Of the three
diﬀerent kinds of advertisements, the FDA regulates “reminder” and “product claim” advertisements. “Help-seeking” adver-
tisements are not regulated by the FDA. Statement by Janet Woodcock, M.D., Director, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration, before the Senate Special Committee on Aging, July 22, 2003, online at
http://www.fda.gov/ola/2003/AdvertisingofPrescriptionDrugs0722. html.
143Ceccoli 154.
144Kathryn Aikin, Division of Drug Marketing, Advertising, and Communications, U.S. Food and Drug Administra-
tion, “Direct-to-Consumer Advertising of Prescription Drugs: Patient Survey Results,” October 22, 2002, online at
http://www.fda.gov/cder/ddmac/Presentations/KitHMCC2002out/.
145Ceccoli 156. Despite its tremendous impact on modern American society, DTC advertising is a relatively new phenomenon.
It was only in the early 1980s that drug companies began marketing their products directly to patients. Statement by Janet
Woodcock, supra note 142. Throughout most of the twentieth century, drug companies promoted their products exclusively to
physicians. Carol Lewis, “The Impact of Direct-to-Consumer Advertising,” FDA Consumer, U.S. Food and Drug Administra-
tion, March-April 2003, online at http://www.fda.gov/fdac/ features/2003/203 dtc.html.
41grown at a rapid rate.146 According to the National Institute for Health Care Management Research and
Educational Foundation (NIHCM), pharmaceutical companies spent approximately $2.5 billion on DTC
advertising in 2000—up from $1.1 billion in 1997, $610 million in 1996, and $44 million in 1990.147 Again,
the ﬁgures for 2005 are likely much higher. To grasp just how much money is involved in these promotional
eﬀorts, consider the following: In 2000, more money ($160.8 million) was spent on DTC advertising for
a single drug—Merck’s now-discredited arthritis and acute pain drug, Vioxx—than was spent to promote
Pepsi ($125 million) or Budweiser ($146 million).148
When it comes to AD/HD in particular, DTC advertising has likewise had a tremendous impact. This can
perhaps best be seen by looking at the case of Strattera, the newest AD/HD drug on the market. Eli Lilly,
the manufacturer of Strattera, has hoped that the drug will help make up for the loss of revenue that resulted
after the expiration of the company’s patent on Prozac several years ago.149 These hopes are not unrealistic
because Strattera has a number of unique competitive advantages over rival AD/HD drugs. Perhaps its
main selling point is that it is the ﬁrst drug speciﬁcally approved to treat adult AD/HD. This gives the
company broader market reach, since it is the only market participant allowed to advertise to adults with
AD/HD.150 Second, Strattera is a non-stimulant, which means that it does not have many of the side eﬀects
that traditionally come with stimulants, such as addiction, weight loss, and insomnia. Strattera may play a
major role in the treatment of individuals who do not respond at all to the stimulants or who do not respond
146Ceccoli 155. The importance of advertising in general can be seen from the following fact: On the whole, pharmaceutical
companies actually spend more money on marketing and promotion than on research and development. Families USA, a non-
proﬁt organization, looked at the SEC ﬁnancial reports of nine major pharmaceutical ﬁrms. In its report, “Proﬁting from Pain,”
the group found that all nine companies spent more on marketing, advertising, and administration (MAA) than on research
and development (R&D). Furthermore, eight of the nine companies spent more than twice as much on MAA than on R&D.
For the nine ﬁrms, the average percentage of revenues devoted to MAA was 27%, compared to just 11% for R&D. See Families
USA, Proﬁting from Pain: Where Prescription Drug Dollars Go (Washington, D.C.: Families USA Foundation, 2002), online
at http://www.familiesusa.org/site/ DocServer/PPreport.pdf?docID=249; Ceccoli 133.
147Cited in Ceccoli 155; Diller 139.
148Cited in Ceccoli 156.
149Editorial, “As Prozac fades, Strattera soars,” The San Francisco Chronicle, December 29, 2003, p. A14.
150Linda Liu, Frost & Sullivan, “Strattera: Redeﬁning Success in AD/HD Therapy,” October 8, 2003, online at
http://www.hospitalpharma.com/PressReleases/pressrel.asp?ROW ID=258.
42well to such drugs.151 Third, because Strattera is a non-stimulant, it is the ﬁrst AD/HD drug that is not a
Schedule II controlled substance. Therefore, Eli Lilly can market the drug more eﬀectively with samples.152
To promote all these beneﬁts, Eli Lilly has launched a marketing campaign unprecedented in scope. The
company has ﬂooded the consumer market with advertisements. It has paid for thousands of television
commercials on channels such as Nickelodeon and Lifetime.153 It has placed advertisements in two-dozen
publications, including Redbook, Parade, and Good Housekeeping.154 People have also seen Strattera
advertisements in brochures, letters, ﬂyers, pharmacy counter displays, billboards, newspapers, on the
radio, in the mail, and, of course, on the Internet. Such an aggressive approach by the company has
paid oﬀ. Physicians wrote more than one million prescriptions for Strattera in its ﬁrst six months on the
market.155 Prescriptions doubled to two million during the next three months KSKen ShaitelmanKSKen
Shaitelman.156 Such ﬁgures mean that Strattera has had the most successful launch of any psychiatric
medication in history.157
How, however, does this huge advertising blitz aﬀect consumers and their overall access to information about
AD/HD? One thing is for certain: there is clearly more information about AD/HD in the marketplace.
And this increased volume of information serves important functions. It helps educate consumers about
AD/HD. It serves to increase the detection of the disorder and alert people who may not be receiving
needed treatment. As was mentioned above in connection with the discussion of the “four communities”
study, there is great concern among mental health professionals that many people with AD/HD are not
receiving appropriate treatment. DTC advertisements clearly serve a valuable function in ferreting out these
individuals.158 Increased information ﬂow also educates consumers about the drugs available to treat the
151DuPaul and Stoner 194.
152Herman Saftlas, “Lilly’s Pipeline of Plenty,” Business Week Online, December 9, 2002, online at
http://www.businessweek.com/investor/content/dec2002/pi2002129 5751.htm.
158That DTC advertisements allow people to play a more proactive role in maintaining their health is clear. In a survey,
Kathryn Aikin and John Swasy asked participants: “Has an advertisement for a prescription drug ever caused you to look for
43disorder.
Less obvious, however, are the ways in which the pharmaceutical companies’ DTC campaigns harm con-
sumers. First, there is the problem that DTC advertisements sweep indiscriminately. Although the message
contained in the advertisements may reach untreated individuals who need help, it also reaches those in-
dividuals who are perfectly healthy yet worry about undiscovered health problems. That savvy marketing
campaigns can seduce people into thinking that they are sick when they are not is a major concern.159 In
2002, 18% of survey respondents said that an advertisement for a prescription drug had led them to ask a
physician about a medical condition or illness that they had not talked to a doctor about before.160 When
it comes to AD/HD, this capacity to inﬂuence is particularly worrisome. The symptoms of the disorder
are so common—ﬁdgeting, short attention span, impulsivity, etc.—that anyone hearing them in the context
of an advertisement will think that he has a medical disorder. “Are you disorganized?” says one Strattera
advertisement. “Do you procrastinate, ﬁdget, lose things?” As Sally Satel relates, this sounds like just about
everyone.161
more information, for example, about the drug or about your health?” 51% said yes. Kathryn Aikin and John Swasy, U.S. Food
and Drug Administration, “Analysis of the Eﬀects of Direct-to-Consumer Advertising on Patient Information-Seeking Behavior,”
October 22, 2002, online at http://www.fda.gov/cder/ddmac/Presentations/aiknDIAdtc701/. Physicians also believe that DTC
advertising can positively inﬂuence their interactions with their patients. For example, most doctors seem to think that because
their patients saw a DTC advertisement, they asked more thoughtful questions. Statement by Janet Woodcock, supra note
142.
159Dr. Arthur Caplan, chairman of the Department of Ethics at the University of Pennsylvania Medical School, suggests that
drug companies may be pushing “self-generated diseases” to sell medicines to individuals who do not have actual problems
but who can be led to believe they might by savvy marketing campaigns. Bill Hendrick, “Attention, please,” The Atlanta
Journal-Constitution, September 14, 2003, p. 1LS. Other practitioners and scholars also subscribe to such a view. See, e.g.,
David Healy, The Creation of Psychopharmacology (Cambridge, Massachusetts: Harvard University Press, 2002) (especially p.
372, regarding the marketing of depression).
160Statement by Janet Woodcock, supra note 142.
161Sally Satel, M.D., “ADD Overdose?” The Wall Street Journal, July 23, 2003, online at http://aei.org/news/news
ID.18076,ﬁlter.all/news detail.asp.
44Another major problem with DTC advertisements is that they make people believe that all of their problems
are biologically based and that taking a pill will make all the problems disappear. The advertisements, in
other words, overstate the eﬃcacy of drugs.162 With regard to AD/HD, although there has been an increasing
push in recent years to recognize the disorder as biologically based, there is still a consensus among experts
that AD/HD is a disorder inﬂuenced by factors other than biology, such as learning disabilities, family
dynamics, classroom size, and economic and cultural issues.163 (Recall the NIMH guidelines on multimodal
treatment, which try to take into account all these non-biological factors.) When DTC advertisements for a
particular medication minimize the importance of social and environmental factors in treatment, they do a
disservice to people who are using the medication, because these people are often convinced that the pill is
a panacea. Therefore, these individuals do not seek out treatments targeted at the non-biological causes of
the disorder.164
A ﬁnal concern about DTC advertisements is that they often understate the side eﬀects of medications. In
a 2002 survey, of those respondents who stated that a DTC advertisement had caused them to seek more
information about a drug, 61% said that they were looking for information about side eﬀects.165 In fact,
in the letters that the FDA issues to pharmaceutical companies about misleading DTC advertisements,
“inadequate conveyance of risk information” is one of the most common violations cited.166 As a result of
such deﬁciencies, doctors often ﬁnd that they have to provide additional information to patients and correct
162In a survey released in January 2003, 58% of respondents agreed strongly that DTC advertisements make drugs seem better
than they really are. Lewis, supra note 145. Also, approximately 75% of doctors said that DTC advertisements make patients
think that a drug works better than it actually does. Id.
163Diller 103.
164Put another way, this improper focus on medication is the result of a lack of balance in advertising. Large pharmaceutical
companies make billions of dollars a year in proﬁts. They have tremendous resources and can aﬀord to put money into expensive
advertising campaigns. However, alternative therapies—such as cognitive-behavioral therapy or psychotherapy—do not have
that kind of marketing muscle.
165Statement by Janet Woodcock, supra note 142.
166Id.
45misconceptions about the medications. It is easy to see why doctors feel the need to do this. Information
about a medication’s side eﬀects is crucial for a patient. It often plays a key role in whether the individual
is willing to start treatment using a particular medication. If the medication, for example, causes insomnia
or weight loss, as some AD/HD drugs do, a person may want to avoid the drug. Even Strattera, which is
billed as a drug that avoids the heinous problems associated with stimulants, has its own set of side eﬀects.
Despite the advantages discussed above, it is clear that DTC advertisements are harmful to consumers in
a number of ways. Can anything be done, however, to limit the harmful eﬀects of these advertisements?
Regarding the understatement of risk information by the drug companies, the FDA can certainly send out
letters, as it has done, warning the companies about deceptive practices. The agency certainly has the au-
thority to do this pursuant to Section 502(n) of the Federal Food, Drug, and Cosmetic Act.167 If the problem
persists, governmental authorities can also bring suits against oﬀending pharmaceutical manufacturers. In
New York, for example, Attorney General Eliot Spitzer sued GlaxoSmithKline for hiding vital information
from the public about the safety and eﬃcacy of Paxil, a drug designed to combat depression, social anxiety
disorder, and a variety of other illnesses.168
However, as to the other problems inherent in DTC advertisements—the companies tricking people into
thinking they are sick, and people believing that pills are a panacea—it does not appear that there is any
easy solution. This is largely a result of First Amendment concerns.169 The Supreme Court’s decision in
2002 in Thompson v. Western States Medical Center makes clear that FDA restrictions on the ﬂow of
16721 U.S.C. 352(n). Section 502(n) of the Federal Food, Drug, and Cosmetic Act provides the FDA with authority to regulate
prescription drug advertisements.
168Jonathan Mahler, “The Antidepressant Dilemma,” The New York Times Magazine, November 21, 2004.
169Much of my discussion here on the First Amendment is based upon a wonderful and extremely comprehensive—albeit
industry-friendly—article by George W. Evans and Arnold I. Friede, entitled “The Food and Drug Administration’s Regulation
of Prescription Drug Manufacturer Speech: A First Amendment Analysis,” 58 Food Drug L.J. 365 (2003).
46information from drug manufacturers to consumers is subject to First Amendment review.170 The scope
of this review depends substantially upon the form of a given DTC advertisement. However, with all of
the forms of advertisement currently used by the drug companies, it appears that the companies and their
advertisements will receive substantial protection from regulation. For example, there are the advertisements
that do not promote a speciﬁc product in a commercial manner, but rather act to educate consumers—e.g.,
“help-seeking” advertisements, which simply describe particular conditions and encourage consumers to
see their doctor for diagnosis and treatment.171 Such advertisements are entitled to the highest degree
of First Amendment protection, and any attempt to regulate them triggers the highest degree of judicial
scrutiny—strict scrutiny. When governmental restrictions are evaluated under this standard, courts require
the government to meet a very strict burden before the restrictions are upheld.
All of the other kinds of DTC advertisements currently in use by the drug companies largely fall into the
category of “commercial speech.” Communication is categorized as commercial speech to the extent that
it aims to promote directly the purchase of a speciﬁc product. For example, the DTC advertisements
in magazines and on television that push Strattera and that encourage consumers to ask their doctors if
Strattera might be right for them are considered instances of commercial speech.172 With such speech, the
FDA has “somewhat greater latitude in controlling manufacturer eﬀorts to promote product sales,” but it
still faces diﬃcult hurdles in its attempts to regulate.173
In Central Hudson Gas & Electric Corporation v. Public Service Commission, the Supreme Court formulated
a four-pronged test to evaluate governmental restrictions on commercial speech.174 When it comes to the
170Thompson v. Western States Medical Center, 122 S. Ct. 1497 (2002).
171Evans and Friede, 58 Food Drug L.J. at 425.
172Id.
173Id. at 367.
174Central Hudson Gas & Electric Corporation v. Public Service Commission, 447 U.S. 557, 566 (1980).
47regulation of DTC advertisements, each of these prongs poses distinct problems. The ﬁrst, and threshold,
prong of the test looks at whether the speech is “false or misleading” in any way. Commercial speech that
creates a false basis for commercial transactions or is misleading in some overt way can be restricted and/or
banned. Courts, however, are reluctant to conclude that commercial speech is false or misleading unless the
government provides evidence to substantiate its claim of deception.175 This requirement poses tremendous
problems for the FDA. The FDA has established no standards or procedures for determining whether a given
communication is false or misleading. For example, as George W. Evans and Arnold I. Friede point out, the
FDA has not decided whether communications can be interpreted on their face or whether they require a
“harder look.”176
Even if the FDA did have procedures in place, it is not clear that the agency could make the requisite
showing that certain DTC advertisements are false or misleading. People most commonly consider DTC
advertisements to be false or misleading because the advertisements provide an incomplete picture of the
drugs at issue, omitting important information about side eﬀects, eﬃcacy, etc. However, such omissions,
even if proven conclusively, do not necessarily cause the DTC advertisement to be false or misleading. The
Supreme Court has stated, in several instances, that the fact that truthful commercial speech may not convey
“exhaustive information” about a product does not automatically make it false or misleading.177 Evans and
Friede write, “Even when advertising communicates only an incomplete version of the relevant facts, the
First Amendment presumes that some accurate information is better than no information at all.”178
Given how diﬃcult it is to show that a given DTC advertisement is false or misleading, proponents of
175Evans and Friede, 58 Food Drug L.J. at 384.
176Id. at 385.
177Id. at 411. See Central Hudson, 447 U.S. at 562. See also Bates v. State Bar of Arizona, 433 U.S. 350, 375 (1977) (holding
that “incomplete” attorney advertising was not inherently misleading).
178Evans and Friede, 58 Food Drug L.J. at 384.
48governmental regulation usually have to turn to the other three prongs of the Central Hudson test. These
prongs mandate that commercial speech can be regulated only if it advances a “substantial” government
interest, where the proposed regulation “directly advances” the government interest asserted, and where the
regulation is “not more extensive than is necessary to serve that interest.”179 Like the part of the test looking
to see whether the speech is “false or misleading,” however, each of these prongs poses problems for those
pushing for governmental regulation of DTC advertisements. Perhaps the most troublesome prong is the
one requiring the government to articulate its “substantial interest” in regulation. Those advocating stricter
FDA regulation of DTC advertisements have pointed to a number of potential governmental interests that
would justify the regulation of DTC advertisements. Over the years, however, courts have found few of these
interests to be “substantial,” much less legitimate. For example, perhaps the most common governmental
interest asserted to justify regulation of DTC advertisements is that regulation would prevent consumers
from using drugs unnecessarily or inappropriately (e.g., when, although healthy, consumers are convinced
after viewing a savvy DTC advertisement that they have an illness). Such a justiﬁcation, however, is based
on an unsupported assumption on how people act. The Supreme Court in Western States said that the
use of such unsupported assumptions constituted disfavored governmental paternalism.180 In that case, the
Court noted that if the government had argued that a restriction on compounded drug advertising was
necessary as a result of a fear that such advertising would “put people who do not need such drugs at risk
by causing them to convince their doctors to prescribe the drugs anyway,” such a fear would fail to justify
the restriction.181 The Court stated that “a fear that people would make bad decisions if given truthful
information” cannot validate a restriction on “the dissemination of truthful commercial information.”182
179Central Hudson, 447 U.S. at 566.
180See Western States, 122 S. Ct. at 1507-1508; Evans and Friede, 58 Food Drug L.J. at 425-426.
181See Western States, 122 S. Ct. at 1507.
182Id.; see also Evans and Friede, 58 Food Drug L.J. at 379.
49Similarly, the FDA might assert that regulation of DTC advertisements would serve the economic and ﬁscal
interest of the government—by, for example, “operating so as to reduce Medicare costs through regulations
that eﬀectively suppress DTC advertisements and thereby suppress demand for advertised drugs.”183 But
such a justiﬁcation is also problematic, because the idea of keeping people ignorant of potentially appropriate
medical treatments in order to advance the government’s economic and ﬁscal goals is morally questionable,
and therefore may not be seen as legitimate. Furthermore, as Evans and Friede point out, it is not clear
that a government’s desire to limit costs is a cognizable interest under the Central Hudson test.184
Even assuming that the FDA can articulate a “substantial” interest in restricting DTC advertisements, it
is still questionable whether the governmental restrictions would “directly advance” the substantial interest
asserted or whether they would be “not more extensive than is necessary to serve that interest.”185 With
regard to the question of “direct advancement,” the issue, in other words, is whether the restrictions on
speech “will in fact alleviate the asserted harm to a material degree.”186 In the case of DTC advertisements,
it will be diﬃcult for the FDA to satisfy this requirement. As suggested above, there are many sources
of information in the marketplace for pharmaceuticals—and especially so when AD/HD is involved. Many
speakers, other than the drug manufacturers, communicate information. Take CHADD, for example. Even
if the FDA did regulate drug manufacturer speech and DTC advertisements, consumers nonetheless would
still be exposed to messages from these other speakers—messages that cause a similar harm. Therefore,
restrictions on DTC advertisements would not in fact alleviate the asserted harm to any material degree.187
The ﬁnal prong of the Central Hudson test—looking to whether the government’s restriction on speech is
183Evans and Friede, 58 Food Drug L.J. at 425.
184See id. at 437, note 388.
185Central Hudson, 447 U.S. at 566.
186Edenﬁeld v. Fane, 507 U.S. 761, 770-771 (1993).
187Evans and Friede, 58 Food Drug L.J. at 386, 427.
50“narrowly tailored” so that the restriction is not more extensive than is necessary to serve the “substantial
interest” asserted by the government—is likewise diﬃcult for the government to meet. Courts assess whether
a regulation is “narrowly tailored” by looking to the “ﬁt” between the means used by the government (the
restriction) and the ends sought (the elimination of the harm). Although the ﬁt between the means and
ends do not have to be perfect, some precision is necessary. Courts will assess that precision by looking to
the availability of regulatory alternatives.188 Therefore, if the FDA seeks to have any restriction on DTC
advertising upheld, it has to show that there are no other, less-burdensome alternatives to the restriction that
would allow it to achieve its objectives. In the case of DTC advertising, however, a less-speech-restrictive
alternative is available: the use of disclaimers and disclosures to limit any harm stemming from problematic
DTC advertisements.189 The FDA was unable to satisfy this prong in Western States, with the Court noting
that the legislative record contained “no hint that the Government even considered ...alternatives” to its
outright restriction on speech.190
Given all these obstacles in the First Amendment arena, it is not clear that much can be done to alleviate
many of the harms that stem from DTC advertisements. If the FDA seeks to have greater success in the
future in regulating DTC advertising, it needs to take several steps. First, the agency needs to develop clear
standards and procedures for determining when exactly a DTC advertisement is to be considered “false or
misleading.” Second, the agency has to be creative in deﬁning new and substantial interests that it can assert
to justify regulating drug manufacturer speech. This is no easy task, given that a wide variety of rationales
for regulation have already been asserted before the courts, and nearly all of them have been struck down.
Third, the FDA must also cope with the reality that the harms that it seeks to combat derive from many
diﬀerent sources. A restriction solely on DTC advertisements would not do all that much to eliminate
188Id. at 386-387.
189Evans and Friede, 58 Food Drug L.J. at 387, 428.
190Western States, 122 S. Ct. at 1507; Id. at 387.
51these harms. This fact alone might discourage the FDA from engaging in further eﬀorts to regulate DTC
advertising. The “inevitability” of certain messages reaching consumers may convince agency oﬃcials that
the FDA’s resources are better spent elsewhere. Finally, the FDA should consider whether there are other,
less-speech-restrictive alternatives that would allow it to achieve its objectives. Expanded use of disclaimers
and more extensive disclosures by drug manufacturers may provide at least a limited remedy for some of the
problems caused by suggestive and savvy DTC advertisements.
V. Doctors
In the previous section, I described Eli Lilly’s eﬀorts to market Strattera through a massive DTC advertising
campaign. This story, however, was incomplete. In addition to its focus on consumers, the company also
targeted another key constituency—doctors.191 To promote the beneﬁts of Strattera to physicians, the
company added, in the ﬁrst six months of 2003, 4000 sales representatives to its already gargantuan U.S.
sales force of 5300. Between January and June 2003, these representatives made 542,000 presentations to
physicians.192 The company also made a concerted eﬀort to seek out psychiatrists in particular—a strategy
that diﬀerentiated the company from its competitors.193
These eﬀorts were worthwhile, because Eli Lilly understood that even with all its advertising directed at
consumers, it is the doctors who ultimately diagnose patients and prescribe medication. Patients may be
convinced, after viewing a DTC advertisement, that they have AD/HD, but if they want a prescription for
191According to an October 2002 GAO report, “Promotion to physicians accounted for more than 80 percent of all promotional
spending by pharmaceutical companies in 2001.” United States General Accounting Oﬃce, Prescription Drugs: FDA Oversight
of Direct-to-Consumer Advertising Has Limitations, GAO-03-177 (Washington, D.C.: GAO, 2002), p. 3.
192Editorial, “As Prozac fades, Strattera soars,” supra note 149. This number dwarfs the 270,000 pitches made by Concerta
representatives and the 163,000 by Adderall representatives during the same time period. See id.
193Liu, supra note 150.
52Strattera, Ritalin, Adderall, or any of the other AD/HD drugs, they are going to have to visit their doctors.
This power of prescription—combined with the fact that doctors, more than any other party, are the ones
expected to be knowledgeable about AD/HD and the range of treatments for the disorder—means that
doctors are some of the most important providers of information about AD/HD.194
A number of factors, however, have conspired to prevent doctors from carrying out their responsibility to
patients to provide complete and accurate information about AD/HD. Perhaps the single most important
factor has been the rise of managed care in the United States. For a number of reasons, managed care
systems cause tremendous problems for doctors.195 First and foremost, they limit the amount of time that
physicians can spend with patients. This is a cause for great concern when AD/HD is involved. As suggested
above, because of the interpretive nature of the AD/HD diagnosis and the high degree of comorbidity that
is present, diagnosing the disorder is immensely diﬃcult. Doctors need to conduct a comprehensive and
thorough assessment to be certain that a given individual is aﬄicted with AD/HD. This includes direct
observation, as well as review of a person’s developmental, social, academic, and medical history. It should
also include input from parents, spouses, friends, teachers, and supervisors.196 Such an assessment, needless
to say, takes time.197 Pressed to get things done quickly by managed care “utilization reviewers,” doctors
are often not able to perform the full work-up that they need to do.
194In other words, the physician is the “learned intermediary.”
195For a more detailed discussion on how managed care systems aﬀect the practice of psychiatry, see Alan A. Stone,
“Psychiatry and the Law,” in Harvard Guide to Psychiatry (Cambridge, Massachusetts: Belknap Press, 1999), pp. 798-823;
Alan A. Stone, “Paradigms, Pre-Emptions, and Stages: Understanding the Transformation of American Psychiatry by Managed
Care,” International Journal of Law and Psychiatry, Vol. 18, No. 4, pp. 353-387 (1995); Alan A. Stone, “Managed Care,
Liability, and ERISA,” Forensic Psychiatry, Vol. 22, No. 1, pp. 17-29 (March 1999).
196Statement by Michael M. Faenza, President and CEO, National Mental Health Association, in Attention-
Deﬁcit/Hyperactivity Disorder, supra note 11.
197Dr. David Fassler, chairman of the Council on Children, Adolescents, and Their Families of the American Psychiatric
Association, says, “You can’t do [diagnosis] in one or two sessions. A comprehensive evaluation means getting a detailed history
of the child’s early development, medical conditions and problems in school and with friends, as well as meeting with the child
and the family.” Susan Gilbert, “Gains in Diagnosing Hyperactivity,” The New York Times, June 20, 2000, p. 8. According
to Diller, a sound and ethical evaluation of someone for AD/HD takes approximately four hours. Diller 212.
53This time limitation on doctors has tremendous implications for the provision of AD/HD information. If
doctors are not doing the comprehensive and thorough evaluation that is required to diagnose AD/HD, they
do not know whether a patient truly has the disorder or not. And if they do not know the true condition of
the patient, how could they possibly be in a position to provide accurate information to the patient about
eﬀective methods of treatment? Lacking a full and complete picture of the patient’s condition, many doctors
have resorted to using AD/HD medication as a diagnostic tool and engage in the practice of prescribing
medication presumptively. However, for reasons discussed below, this practice is one that is deeply ﬂawed.
A second problem caused by managed care systems is that they do not readily pay for access to specialists.
Most managed care plans allow patients to see specialists only after a referral by a primary care doctor.
The primary care doctor, however, is given a limited and preset amount of money (called a capitation
fee) to handle all of a patient’s problems. If the primary care doctor refers a patient to a specialist, he
will lose a portion of that capitation fee and suﬀer direct economic loss. Therefore, there is a built-in
disincentive for primary care doctors to make specialist referrals. If the primary care doctor does actually
provide a referral, that is not the end of the story, however. There are additional restrictions that patients
and medical practitioners have to contend with. The specialist is usually allowed to provide to the patient
only one full visit of about 50 minutes and two 20-minute follow-up appointments to monitor the results of
medication.198 The result of all this is that the people best qualiﬁed to provide information about AD/HD—
certain psychiatrists with specialized AD/HD training, as well as behavioral-developmental pediatricians—
are not doing so.199
198Diller 169.
199This is not only a problem relating to lack of access. It is also a problem of shortage. There is a major national shortage
of child and adolescent psychiatrists. There are only about 7400 child and adolescent psychiatrists in America; the number of
children and adolescents believed to suﬀer from mental illnesses, however, is between 15 and 20 million. Even in areas where
there are many of these physicians, the average wait to see one is approximately six weeks. Mahler, supra note 168; Statement of
Lance Clawson, in Protecting Children, supra note 4. The American Academy of Child and Adolescent Psychiatry (AACAP)
has recommended Congressional action to remedy this problem, including passage of the Child Healthcare Crisis Relief Act,
54Not only are the people best qualiﬁed to provide information not doing so; the lack of access to AD/HD
specialists means that primary care doctors, who often do not have the necessary training and knowledge to
deal with AD/HD, are the ones providing information about the disorder. In a survey conducted at New York
University, only 34% of 400 primary care doctors said that they felt “very” or “extremely” knowledgeable
in treating AD/HD.200 Yet in the vast majority of cases, it is these doctors who are providing information
about the disorder to patients. Such results are disturbing, to say the least. These doctors simply have not
undergone the training required to conduct extensive AD/HD evaluations. In patient interviews, they do not
know what to ask or what to look for. And in the treatment of the disorder, they are often similarly clueless.
For example, there are at least ﬁfteen diﬀerent medications used to treat AD/HD. There is Dexedrine,
Adderall, Concerta, Ritalin, and Strattera, to name a few. How are primary care doctors to choose among
these drugs? They cannot—they simply do not have the training or the necessary clinical experience to
diﬀerentiate these drugs.201 Specialists at least are more familiar with these medications because of their
specialized training and because they presumably prescribe these medications on a more regular basis and
therefore have a better opportunity to observe their clinical eﬀects.
As a result of this lack of specialized knowledge and unfamiliarity with treatment modalities, many of the
doctors who diagnose and treat AD/HD make assumptions that are completely incorrect. For instance, it is
a common practice among doctors to engage in “oﬀ-label” prescribing—i.e., the prescribing of a medication
“in a diﬀerent dose, for a longer duration of time, for a diﬀerent age group, or for a diﬀerent medical
H.R. 1359, bipartisan legislation sponsored by Representatives Patrick Kennedy (D-RI) and Ileana Ros-Lehtinen (R-FL), which
would have encouraged individuals to enter children’s mental health professions through the creation of education incentives.
The bill lapsed, however, at the conclusion of the 108th Congress. Id.
200Cited in Donna Halvorsen, “Growing up restless,” Star Tribune (Minneapolis, MN), September 16, 2003, p. 1E.
201One might posit that the primary care doctor would choose a drug after examining its side eﬀects. But this assumes too
much—most doctors do not know anything about side eﬀects. According to the FDA, less than one percent of doctors actually
know the side eﬀects of the drugs that they are prescribing. Cited in Mary Ann Block, D.O., in Attention-Deﬁcit/Hyperactivity
Disorder, supra note 11. (This brings to mind an apt quote by Voltaire: “Doctors pour drugs of which they know little, / To
cure diseases of which they know less, / Into human beings of whom they know nothing. Cited in Ceccoli 1.) There is no way
that doctors can talk knowledgeably to a patient about side eﬀects if they themselves do not know about them.
55indication than recommended in the prescribing information.”202 When primary care doctors engage in oﬀ-
label prescribing in treating AD/HD, they often do so on the mistaken assumption that AD/HD medications
aﬀect adults and children similarly. Therefore, they just adjust the dosage according to the age of the patient.
But these physicians fail to grasp one basic fact—adults and children often metabolize drugs in diﬀerent
ways. The liver, where many mechanisms of drug metabolism occur, may be relatively much larger in a child
than in an adult. As one writer puts it, “compare a 60-pound child with a three-pound liver to a 200-pound
adult with a four-pound one.”203 Furthermore, the amount of time that a drug remains in the blood can
diﬀer tremendously in the two populations.204 Therefore, drugs that work just ﬁne in adults may not be
best for children, and vice versa.205
Similarly, as stated above, many doctors also use AD/HD medications as diagnostic tools, saying to their
patients, “Let’s try the drug and see if it works.” In other words, if the drug seems to improve attention,
the patient is assumed to have AD/HD. But this reasoning is ﬂawed, because most AD/HD drugs work
202E. Clarke Ross, “When It Comes to Diagnosing and Treating AD/HD, ‘Evidence-Based’ Methods Best,” Orlando Sentinel
Tribune, September 7, 2003, p. G4. Doctors are supposed to tell patients when they are prescribing a drug for oﬀ-label
purposes, but many do not do so. As Lawrence Diller relates, there are a number of reasons for this—“absent-mindedness,
haste, or concern that the information will unnecessarily worry the patient and make compliance less likely.” Diller 268.
203Karen Patterson, “A Dearth of Data,” The Dallas Morning News, April 13, 2003, p. 1H.
204Id. There is yet another diﬀerence that primary care doctors often fail to recognize: Children’s brains are still developing,
and there is great concern about the eﬀect of psychotropic drugs on brain functioning. This is not something that the doctors
have to worry about with adults.
205Historically, there has not been much pharmaceutical research examining the eﬀects of drugs in children. There are a
number of reasons for this: First, ﬁnding people willing to volunteer for the work and commit to it for a period of many years
is no simple task. In any extended research study, the attrition rate is high, but this is especially true when the subjects
are children. Children tend to become easily bored and lose interest in the project. Furthermore, they eventually leave for
college, thereby precluding further follow-up. Jeﬀrey Kluger, “Medicating Young Minds,” Time Magazine, November 3, 2003,
p. 48. (Even though thousands of studies have been undertaken on Ritalin and AD/HD, very few have followed into adulthood
children who took the drug. Diller 42.) Approximately 40% of children drop out of long-term research studies before the work
is done. Kluger, “Medicating Young Minds.” Second, most parents are justiﬁably concerned about the side eﬀects of untested
drugs. Third, many studies require the use of brain scans, and such scans involve at least a little exposure to radiation—a
fact most parents are reluctant to embrace, particularly if their children are not suﬀering from any disorder and are simply
being used as a “control” to establish the look of a healthy brain. (Getting good scans from children with AD/HD presents an
additional problem, as holding still is not something they do well.) Kluger, “Medicating Young Minds.” Congress, however, has
attempted to address this lack of pediatric research by enacting the FDA Modernization Act of 1997. The FDA now provides
an additional six months of exclusive marketing rights to any company examining a drug’s eﬀects on a minimum of 100 children
for more than six months. Kluger, “Medicating Young Minds.” As a result of this incentive, pediatric research has grown over
the last seven years.
56for everyone, regardless of the presence of AD/HD. Psychostimulants such as methylphenidate allow nearly
everybody to concentrate on things that they ﬁnd boring.206 Judith Rapaport of the NIMH, in studies
conducted during the mid-1970s and early 1980s, showed convincingly that psychostimulants improve the
ability of most people to concentrate on tasks requiring good attention, regardless of whether they have
AD/HD.207 Attentional improvement after psychostimulant treatment therefore is not at all diagnostic of
AD/HD.208 But doctors who have no expertise with psychostimulants are not likely to know this.
A third and ﬁnal problem with the managed care system is that it has increased pressure on doctors to
prescribe medication rather than spend time talking with patients or their families. Managed care companies
pay physicians more for “cutting” or “zapping” or prescribing medication than for talking with patients
(something known as “cognitive time”).209 But in the diagnosis and treatment of AD/HD, “cognitive time”
is essential. It is not only when the doctor is evaluating the patient; it is also when a dialogue takes place
between patient and doctor. The patient can ask questions about AD/HD during this time and follow up
about treatment. It is also the time that the patient can alert the doctor about prior treatments and about
individual attitudes relating to the use of medication in general.
Although the managed care system is certainly the cause of many problems aﬀecting doctors’ ability to
provide information about AD/HD, there are other sources of blame. A second key factor aﬀecting AD/HD
information provision is the inﬂuence of the pharmaceutical companies on physicians. At the beginning of
Part V, I discussed Eli Lilly’s attempts to target doctors in the company’s promotion of Strattera. This,
206See Statement of Lawrence Diller, in Ritalin Use Among Youth, supra note 9.
207Livingston, supra note 2.
208“Methylphenidate: A Background Paper,” supra note 37.
209Diller 168. Also, note that by prescribing medication rather than engaging in “cognitive time,” physicians can see more
patients than they would otherwise. Therefore, the economic incentives under managed care favor the use of medication. Peter
N. Spotts, “Chemical Kids,” The Christian Science Monitor, March 6, 2003, p. 14.
57however, is part of a larger eﬀort. Pharmaceutical companies understand how important doctors are to
their plans to sell their products; therefore, they are not content to merely expand the size of their sales
forces or make more product presentations. Their promotion eﬀorts take a variety of other forms as well:
sponsorship of academic research and educational programs, informal interactions between pharmaceutical
company representatives and doctors, and outright bribery. These additional eﬀorts, however, have a major
eﬀect on the quality and quantity of the information that patients receive. Since this is true not only with
AD/HD, but with other illnesses as well, much of my discussion in the following section will focus on the
problem as it exists in medicine as a whole.
To understand how the information provided to patients is tainted by doctors’ associations with the drug
companies, it is ﬁrst necessary to look at some of the diﬀerent ways that these companies seek to win the
“hearts and minds” of doctors. First, the drug companies inﬂuence doctors by sponsoring their academic
research. Virtually all AD/HD researchers take money from the pharmaceutical industry to conduct studies
and run their laboratories. The concern is that this money is inﬂuencing the outcome of the research and
distorting the evidence base of health care.210 One study examining this issue looked at a series of 332
randomized trials, the results of which were published between January 1999 and June 2001 in eight surgical
journals and ﬁve medical journals. The authors found a clear association between industry funding and pro-
industry ﬁndings.211 There is also evidence to suggest that researchers do not publish negative ﬁndings.212
All this has led Arnold Relman, a Harvard professor and former editor of the New England Journal of
Medicine, to say, “The academic institutions of this country are allowing themselves to be the paid agents
210Ray Moynihan, “Who pays for the pizza? Redeﬁning the relationships between doctors and drug
companies” (Part 1: Entanglement), British Medical Journal 326: 1189-1192 (May 31, 2003), online at
http://bmj.bmjjournals.com/cgi/content/full/326/7400/1189.
211See Mohit Bhandari, Jason W. Busse, Dianne Jackowski, Victor M. Montori, Holger Sch¨ unemann, Sheila Sprague, Derek
Mears, Emil H. Schemitsch, Dianne Heels-Ansdell, and P.J. Devereaux, “Association between industry funding and statistically
signiﬁcant pro-industry ﬁndings in medical and surgical randomized trials,” Canadian Medical Association Journal, Vol. 170,
No. 4, February 17, 2004, online at http://www.cmaj.ca/cgi/content/abstract/170/4/477.
212Statement of Lawrence Diller, in “Medicating Kids,” supra note 130.
58of the pharmaceutical industry.”213
Second, pharmaceutical companies play a major role in the education of doctors. To renew their licenses,
doctors are usually required to participate in continuing medical education (CME) classes. These classes,
however, are largely subsidized by the drug companies.214 Most CME classes are taught by experts who are
selected and paid by the companies producing the drugs being discussed, and the experts’ lectures, more
often than not, emphasize the medical beneﬁts of those drugs. Although some of this information does
serve to educate doctors, most of it is simply marketing disguised as education.215 The drug companies
also inﬂuence medical education through more informal means. Pharmaceutical representatives “detail”
the doctors—i.e., they teach them about their company’s products. The representatives—a major presence
all over, but especially at teaching hospitals—work hard to persuade attending physicians and residents to
prescribe the drugs produced by their companies. The result of all of this—the CME classes and the informal
“detailing”—is that most doctors nowadays learn which drugs to use, and how to use them, from individuals
working for the pharmaceutical industry.216
Third, there is outright bribery. Pharmaceutical companies provide countless free “goodies” to doctors.
Often these are small tokens. They include, for example, free pens, ﬂashlights, promotional notepads, and
company-branded stethoscopes. Medical students, interns, and residents in particular rely a great deal on
these gifts. The companies, however, also provide much more expensive treats. These include direct gifts
of travel or accommodation; tickets to sponsored dinners and social or recreational events; stock or equity
213Quoted in Moynihan, “Entanglement,” supra note 210.
214Arnold S. Relman, “Your Doctor’s Drug Problem,” The New York Times, November 18, 2003, p. 25. As one writer
has put it, the result of this is that if a doctor today is too principled to participate in pharmaceutical-sponsored education,
that doctor does not receive much education at all, since so much of it is now ﬁnanced by the drug industry. See Abigail
Zuger, “When Your Doctor Goes to the Beach, You May Get Burned,” The New York Times, February 24, 2004, online at
http://www.nytimes.com.
215Relman, supra note 214.
216Id.
59holdings in the companies themselves; funding for medical schools, academic chairs, or lecture halls; paid
speaking engagements, ranging from $250 to $20,000 a year; paid consultancies, at salaries usually less than
$10,000 but sometimes providing up to $120,000 a year; and paid positions on advisory boards.217 AD/HD
expert Lawrence Diller writes that he has been oﬀered $100 if he would listen to someone talk about AD/HD
for 15 minutes on the telephone and then ﬁll out a ﬁve-minute questionnaire.218
Many of the ways in which the pharmaceutical companies seek to purchase the allegiance of doctors are
extremely creative—so much so that a few of the techniques have their own nicknames. The “dine and dash”
goes as follows: A doctor orders takeout Chinese food, and when he goes to the restaurant to pick up his
order, a pharmaceutical company representative is there, ready to talk with him about the company’s newest
drug. Then, when the food is ready, the representative pays the bill. (This tactic is especially popular near
teaching hospitals, where drug company representatives are certain to encounter hungry residents on their
breaks.) The “gas and go” is another way that pharmaceutical representatives seek to inﬂuence doctors.
The representative approaches the doctor at the gasoline pump as he is ﬁlling up his car with gas after work.
While the tank is being ﬁlled, the doctor is a captive audience, and the drug company representative can
ply his company’s wares. When the car is all ready to go, the representative thanks the doctor for his time
and then pays the cashier.219
Why is this pharmaceutical company activism a problem? The physician-patient relationship is a ﬁduciary
one, and implicit in this is an obligation for the physician to avoid conﬂicts of interest. Doctors should
be concerned about what is best for their patients, not what kind of beneﬁt they themselves will receive
from the drug companies. Gifts from the pharmaceutical industry create tremendous conﬂicts of interest,
and these conﬂicts in turn aﬀect the information that doctors provide to their patients about AD/HD and
217Moynihan, “Entanglement,” supra note 210.
218Diller, “Medicating Kids,” supra note 212.
219Katherine S. Mangan, “Strong Medicine for Doctors,” The Chronicle of Higher Education, January 9, 2004, p. 28.
60other disorders and illnesses. To see that this is so, all one has to do is look at doctors’ prescription habits.
Doctors often prescribe the drugs produced by the companies providing the free gifts and beneﬁts, even
when these drugs are more expensive or have no beneﬁt over cheaper alternatives.220 In an often-cited 1992
study published in the journal Chest, researchers secretly tracked doctors’ use of two drugs before and after
all-expense-paid educational trips to tropical resorts. They found that prescriptions for the two drugs more
than tripled after the trips, an eﬀect that lasted for more than a year, while the use of equivalent drugs
stayed the same.221
Sometimes, when a doctor favors a more expensive drug or a newer drug and there is no medical basis for
doing so, it is the result of a conscious thought process by the doctor. The doctor might purposely prescribe
the drug to thank the drug company for its free dinner or for supporting a particular research proposal. More
often, though, it seems that when a doctor favors a drug company’s products, he is doing so unconsciously.
Almost all doctors, when surveyed, say that their clinical judgment and prescribing habits are unaﬀected
by the activities of drug companies.222 But this belief is completely erroneous, as the following anecdote,
provided by Abigail Zuger of The New York Times, illustrates:
220Dan Shapiro, “Drug Companies Get Too Close for Med School’s Comfort,” The New York Times, January 20, 2004, p.
D5. This is to say nothing of the fact that the free beneﬁts provided to doctors will also make the doctor more likely to choose
a medication over a non-drug treatment. Also, note that by prompting doctors to overprescribe expensive drugs, the free gifts
and beneﬁts are increasing the cost of prescription medicines. Mangan, supra note 219.
221Cited in Zuger, supra note 214. See J.P. Orlowski and L. Wateska, “The Eﬀects of Pharmaceutical Firm Enticements on
Physician Prescribing Patterns. There’s No Such Thing as a Free Lunch.” Chest 1992, 102: 270-273.
222See Zuger, supra note 214. Surveys also reveal, though, that doctors are less conﬁdent about the ability of other physicians
to resist the free gifts and beneﬁts of the pharmaceutical industry. Relman, supra note 214. Abigail Zuger writes, “A doctor
I know maintains a fairly typical relationship with the pharmaceutical industry. He deplores its inﬂuence on medical practice
and worries that his colleagues’ prescribing habits are increasingly swayed by omnipresent drug advertisements and sales agents
pumping new products. Regarding his own independence and integrity, though, my friend has no doubts. He feels that, as a
man of science, he is trained to recognize an advertisement when he sees one, and to ﬁle it away in that corner of his brain
reserved for potentially biased information.” Zuger, supra note 214.
61A new AIDS drug was introduced into the marketplace a while ago, with some interesting
features that set it apart from older drugs. For one thing, it was a new class of drug whose
potency was not altogether certain; for another, it was a long-acting drug that could be taken
once a day—a wonderful and liberating detail for patients otherwise tethered to a twice-
or thrice-daily schedule. The drug was released into the marketplace with a minimum of
published information on its success in patients—not an unusual occurrence in these days
of rapid drug approvals. The pharmaceutical company’s representatives outdid themselves,
introducing their new product with lunches, dinners and far-ﬂung focus groups. My friend
[who Zuger says was convinced that he was not aﬀected by the pharmaceutical company’s
advertisements], a little skeptical of the drug, took full advantage of these opportunities to
learn all about it. After many conversations with the drug representatives, a half-dozen
nice meals and a few trips to warm, sandy beaches, he had plenty of information. Time
passed. More studies were done. The new drug seemed to perform somewhat less eﬀectively
than had been hoped. Advisory bodies began to warn that in some situations, the new
drug should not be used at all: it was so ineﬀective it could get patients into trouble. My
friend, nothing if not conscientious, went through his list of patients to identify those with
H.I.V. infection who were on the new drug, so that he could contact them and change their
pills. The next time I ran into him he was a little subdued, newly conscious of the power
of subliminal advertising. “It turns out I had an awful lot of people on that silly drug,” he
said. “I honestly can’t imagine how that happened.”223
Given all these problems and the seeming inability of doctors to provide unbiased and objective information
about illness and treatment, is there anything that can be done to remedy the situation? With regard to
the issues posed by managed care, a solution for many of the problems will come only with a complete
overhaul of the health care system in the United States. If or when such an overhaul does take place, it
should ideally provide for a system that balances “the increasing market pressures for eﬃciency” with the
need for doctors to spend ample time to correctly diagnose and treat patients.224 Also needed are better
reimbursement schemes for primary care physicians so that they do not face any disincentive when referring
patients to specialists. Specialists are often the ones who possess the necessary knowledge and training to
help patients suﬀering from a particular disorder or illness. This is especially the case with AD/HD.
Concerns about the inﬂuence of the pharmaceutical companies on physicians have already led to a number of
224See Statement of Lance Clawson, in Protecting Children, supra note 4.
62attempts at reform. The American Medical Association, for example, has issued new guidelines restricting
the giving of gifts to doctors. In 2002, the pharmaceutical industry’s trade group, the Pharmaceutical
Research and Manufacturers of America (PhRMA), also enacted voluntary guidelines designed to discourage
the most egregious instances of corporate bribery, such as the lavish meals and the expense-paid trips to
sunny resorts that have no educational purpose.225, 226 Furthermore, a number of academic medical centers
have implemented changes in their programs. They have developed policies that restrict access to medical
students and residents. The University of Michigan, the University of Iowa, and Columbia University, among
others, have limited pharmaceutical industry sponsorship of educational activities, imposed restrictions on
the contact of drug representatives with trainees, and banned gifts.227 Finally, the American Medical Student
Association has been conducting a nationwide campaign called PharmFree that aims to bring an end to the
free gifts, the lavish lunches, the sponsored CME classes, and the paid consultancies. Students are encouraged
to sign a special PharmFree pledge that commits them to seek out unbiased health care information and
to take a revised Hippocratic oath, which reads as follows: “I will make medical decisions ...free from the
inﬂuence of advertising or promotion. I will not accept money, gifts, or hospitality that will create a conﬂict
of interest in my education, practice, teaching, or research.”228
Unfortunately, many of these attempts at reform, and others, have failed to address the issue suﬃciently.
According to Mildred Cho, a biomedical ethicist at Stanford University and someone with an interest in
doctors’ conﬂicts of interest, the new guidelines have “generally done little more than endorse the myriad
225Mangan, supra note 219. Meals and gifts in excess of $100 are discouraged, as are gifts that do not have an educational
use. Therefore, as one writer points out, an $80 medical dictionary or stethoscope would be considered reasonable under the
guidelines. Also, tactics as the “dine and dash” and the “gas and go” are now oﬃcially condemned under the guidelines. Id.
226That these guidelines were adopted voluntarily is perhaps not so much a response to concerns from academics and practi-
tioners as a desire to make a pre-emptive move, before Congress can act on the problem.
227Shapiro, supra note 220.
228Ray Moynihan, “Who pays for the pizza? Redeﬁning the relationships between doctors and drug com-
panies” (Part 2: Disentanglement), British Medical Journal 326: 1193-1196 (May 31, 2003), online at
http://bmj.bmjjournals.com/cgi/content/full/326/7400/1193.
63forms of the existing interactions.”229 Author and reporter Ray Moynihan agrees with Cho. He writes,
“Under the industry’s new voluntary code covering relationships with health professionals, if a company
ﬂies 300 doctors to a golf resort, reimburses their costs, pays them to attend, and educates them about the
company’s latest drug, in order to train them to become members of the company’s stable of paid speakers,
the entire activity would be in compliance.”230 Unfortunately, the medical establishment—and in particular,
the medical educational establishment—tolerates all this. It does not want to do anything to jeopardize the
support of the pharmaceutical industry.231 It also does not seem to care at all about how these policies
aﬀect patients and the provision of information.
Reform, however, is achievable. Any viable and sustainable eﬀort at change requires that the relationship
between physicians and industry be redeﬁned. All hospitals and academic institutions should put in place
guidelines that ensure that doctors are practicing on the basis of evidence rather than promotion.232 Such
guidelines should include, for example, restrictions on the interaction between pharmaceutical company
representatives and doctors; prohibitions on individuals or organizations with conﬂicts of interest teaching
CME classes; restrictions on physicians’ acceptance of “goodies”; and prohibitions on researchers accepting
drug company sponsorship.233 Furthermore, pharmaceutical industry groups need to regulate themselves
more stringently—perhaps by adopting mandatory guidelines. Should they fail to do this, Congress will be
compelled to act. Only if steps such as these are taken can we ensure that conﬂicts of interest in medicine
disappear and that doctors are providing information on the basis of what is best for the patient, not
themselves.
VI. Conclusion
229Moynihan, “Entanglement,” supra note 210.
230Id.
231Relman, supra note 214.
232Mangan, supra note 219.
233Moynihan, “Disentanglement,” supra note 228.
64In this article, I have discussed three of the most important sources of information about AD/HD—the
schools, the media, and doctors. Part III, relating to the schools, describes an area in which substantive
regulation has been attempted. Congress, in deliberating on the merits of the Child Medication Safety
Act of 2003, stated in clear and explicit terms its belief that information about AD/HD emanating from
the schools should be regulated. This makes sense: Allowing teachers and other education professionals to
provide information about a disorder when they are not qualiﬁed to do so should not be permitted. Nor
should teachers and administrators be allowed to condition attendance at a school upon the use of certain
medications. Despite the fact that the Child Medication Safety Act failed to pass Congress, the mere drafting
of the Act shows the legislature’s understanding that regulation of the ﬂow of information about illness and
medication may be necessary to ensure the safety and welfare of individuals.
Part IV, relating to the media, describes an area where regulation is certainly needed, but, as a result
of constitutional and statutory limitations, such regulation is not likely to be forthcoming. The two most
proliﬁc media sources of information about AD/HD—the Internet and DTC advertising—each present certain
problems. The Internet is an area where free speech and First Amendment concerns are paramount. This
makes eﬀective governmental regulation nearly impossible. DTC advertising, in contrast, is an area that is
regulated by the FDA. With its current authority, however, the FDA cannot do much to control the savvy
marketing campaigns in which the pharmaceutical companies trick people into thinking they are sick and/or
make people believe that pills will solve all their problems. This is largely because of First Amendment
concerns that limit the government’s ability to regulate commercial speech.
Finally, Part V, relating to doctors and their role in the provision of AD/HD information, describes an
area where little substantive regulation has been attempted, despite its urgency. However, unlike with the
65media, where there are various limitations on regulation, the regulation of doctors is a task that is easily
achievable. Although many of the problems stemming from the rise of managed care will be ﬁxed only with
a complete overhaul of the health care system in the United States, much can be done to limit the inﬂuence
that pharmaceutical companies have on physicians. Although major restrictions on doctor-pharmaceutical
company interaction are extreme and will likely face resistance from many quarters, such restrictions must
be implemented. The nation’s health is at stake.
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